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The current study assessed alterations to the linear V̇O2p slow component (V̇O2p 
SC)-muscle fatigue development relationship using dietary nitrate (NO3-) supplementation 
during very heavy (VH)-intensity constant-work rate cycling exercise. Using a double-
blind, block-randomised, crossover design, 8 healthy men (age, 24±2 yr [mean±SD]; V̇O2p-
max, 43.8±6.0 mL/kg/min) consumed NO3--rich (BRJ) or -depleted (PLAC) beetroot juice 
daily for 20 d. Participants completed pre/post-condition incremental leg cycling V̇O2p-max 
and 3-min “sprint” verification exercises. An initial 5 d loading phase was followed, on 
alternate days, by single trials of VH- or moderate-intensity exercise at select time points 
with a 14 d washout period separating conditions. Muscle fatigue was assessed pre/post-
exercise by electrically stimulated quadriceps muscle torque production. NO3- 
supplementation had no effect on the development of the V̇O2p SC amplitude or muscle 
fatigue or the linear relationship between the two variables (slope = 6.85 (BRJ) vs. 8.34 
(PLAC) (mL/min)/(10/50 Hz ratio; P = 0.628). 
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Summary for Lay Audience 
When exercising at a constant work rate (WR) the rate of oxygen (O2) consumption 
measured at the lungs (V̇O2p) is also constant. When the WR is increased to a level below 
a threshold exercise physiologists term “lactate threshold” (θL), V̇O2p increases to a new 
“steady state” within 2-3 minutes. If the increased WR is beyond θL, the increase in V̇O2p 
is higher than that which would be predicted by the sub-θL linear relationship between the 
increase in WR and V̇O2p. This extraneous V̇O2p is termed the “V̇O2 slow component” 
(V̇O2p SC), and a steady state is reached over a longer time period (approximately 10 
minutes). When exercising above a higher threshold termed “critical power” (CP), a V̇O2p 
steady state is never reached. Instead, V̇O2p continues to increase until the muscle’s ability 
to utilize O2 is maximised (V̇O2p-max) or the participant discontinues exercise. While the 
determinants of the extraneous V̇O2 is unknown, it has been linked to the progressive 
development of muscle fatigue. Muscle fatigue can be inferred through the decrease in 
muscle torque production induced by involuntary electrical stimulation of the muscle. 
Nitrate (NO3-), a molecular compound commonly found in leafy green foods, has 
been implicated in lowering the V̇O2p at given time points in some studies employing 
constant-WR exercise above CP when consumed as a concentrated form of beetroot juice. 
Additionally, studies have shown an increase in the muscle’s ability to contract with NO3- 
supplementation. Considering these effects, the current study examined how NO3- 
supplementation might influence the linear relationship between the increase in the V̇O2 SC 
development and muscle fatigue, thereby furthering our understanding of muscle function.  
Eight young, healthy men were randomly placed into nitrate and placebo 





various duration whilst measuring V̇O2p. The participants also completed muscle fatigue 
testing prior to and following each test. At the end of each condition, the participants 
switched conditions following a 14 d period without any supplementation and repeated the 
protocol. NO3- supplementation did not alter the linear relationship between the 
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Chapter I: Review of the Literature 
1.1 - Energy Provision Pathways 
In order to support the constant dynamics our bodies endure in day-to-day activities 
(e.g., walking, climbing stairs, higher-intensity exercise, etc), humans require various 
energy provision systems. Under most conditions oxidative phosphorylation provides the 
majority of usable energy for muscle contractions in the form of adenosine triphosphate 
(ATP). To meet the ATP demand in the active muscle, oxygen (O2) must be transferred 
from the atmosphere to the mitochondrion by diffusing through the alveoli of the lungs into 
the blood, and from there it must diffuse to the mitochondrion within the contracting 
myocyte.  
 At rest or during constant-work rate (WR) exercise, oxidative phosphorylation is 
the predominant energy provision pathway. However, with the onset of an elevated WR, 
there is an instantaneous increase in ATP demand by the contracting muscle. While 
oxidative phosphorylation is highly capable of producing ATP within the exercising 
muscle, it cannot provide substrate quickly enough to match the increased ATP 
requirement of the cell at the immediate onset of exercise. Substrate-level phosphorylation 
provides an immediate compensatory response through phosphocreatine (PCr) degradation 
and upregulation of glycogenolysis and glycolysis.  
While substrate-level phosphorylation provides an immediate source of usable 
energy for the muscle cell upon an increase in WR, the length of time that this energy 
provision system can be relied upon is limited, as it contributes to the accumulation of 





hydrogen ions (H+), adenosine diphosphate (ADP), and inorganic phosphate (Pi; Allen et 
al., 2008). Presumably, a faster activation of oxidative phosphorylation with reduced 
reliance on substrate-level phosphorylation would improve exercise tolerance and delay 
the onset of muscle fatigue.  
1.1.1 - Substrate-Level Phosphorylation 
 With a high demand for ATP provision during the onset of exercise, an energy 
system is required that can respond quickly. In exercising muscle, ATP resynthesis is 
provided through upregulation of phosphocreatine (PCr) hydrolysis and 
glycolysis/glycogenolysis activity. Muscle PCr content falls with exercise in an intensity-
dependent manner.  The profile of muscle PCr degradation is dependent on the activation 
of mitochondrial oxidative phosphorylation with PCr reduction slowing as free creatine 
(Cr) is rephosphorylated in the mitochondrial intermembrane space, catalyzed by the 
mitochondrial creatine kinase (CK) in association with oxidative ATP production and 
transfer across the inner mitochondrial membrane (via the Adenine Nucleotide 
Translocase; ANT) – the Cr-PCr shuttle system. This reaction is as described below (Allen 
et al., 2008). 
Equation 1: ATP + Cr ⇌ PCr + H+ + ADP 
 
Following this reaction, the PCr diffuses across the outer mitochondrial membrane 
into the cytoplasm, where cytosolic CK acts as a catalyst for the reverse reaction. This 
system is beneficial relative to ATP diffusing directly from the mitochondrial matrix to the 





molecular weight (211.114g/mol vs 507.181g/mol). Adenylate kinase (AK) can further 
provide ATP through the near-equilibrium reaction (Zeleznikar et al., 1990): 
Equation 2: 2(ADP) ⇌ ATP + AMP 
 
where AMP is an adenine monophosphate molecule. This pathway is advantageous in that 
it resynthesizes at ATP but, importantly, it acts to limit the rise in free ADP (ADPfree) 
concentration, thereby minimizing a fall in the [ATP]-to-[ADPfree] and thus the Gibbs free 
energy of ATP hydrolysis. 
In addition to the PCr shuttle and CK- and AK-catalyzed reactions, glycolysis is 
upregulated at the onset of exercise to provide a near-immediate source of ATP with a 
drawback of higher H+ production relative to oxidative phosphorylation. Glycolysis is a 
ten-step process that ultimately leads to the formation of two pyruvate molecules, two 
reduced nicotinamide adenine dinucleotide (NADH) molecules, as well as a net of two 
ATP molecules if the source of carbohydrate is free glucose in the cytosol (net three ATP 
if the carbohydrate source is stored glycogen). Four ATP are produced in the full sequence 
of glycolysis, but one ATP molecule is required for the phosphorylation of glucose to 
glucose-6-phosphate (catalyzed by hexokinase), and another is required for the 
phosphorylation of fructose-6-phosphate to fructose-1,6-bisphosphate catalyzed by 
phosphofructokinase-1). The glucosyl units from stored glycogen enter the pathway as 
glucose-6-phosphate, bypassing the hexokinase-catalyzed reaction step. This difference in 
ATP hydrolysis becomes important when the muscle is contracting under a state of very 
heavy- or severe-intensity exercise (i.e., above critical power; CP), as the additional ATP 





NAD+ is a critical molecule for glycolysis to function, yet the cytosolic store of 
NAD+ and NADH is limited. During exercise (especially at higher intensities), NADH 
cannot be oxidized (to NAD+) quickly enough via the malate shuttle to maintain a steady 
supply of NAD+ for glycolysis. To accommodate the demand for NAD+, pyruvate formed 
from glycolysis instead becomes reduced to lactate by accepting a hydride ion from NADH 
under the catalysis of the lactate dehydrogenase enzyme to reform NAD+. This pathway is 
vital in the muscle’s ability to continue contracting due to an imbalance between pyruvate 
production (in glycolysis) and the oxidation of pyruvate (via upregulation of mitochondrial 
pyruvate dehydrogenase and oxidative phosphorylation). 
1.1.2 - Oxidative Phosphorylation 
As steady-state conditions are reached during constant-WR exercise, oxidative 
phosphorylation becomes the predominant form of ATP resynthesis in the myocyte. 
Electrons from the reduced equivalents produced in glycolysis (NADH) and the 
tricarboxylic acid cycle (NADH & flavin adenine dinucleotide) enter the electron transport 
chain (ETC) in the inner mitochondrial membrane. These reducing equivalents provide 
electrons that flow through complexes 1-4 to pump H+ to the mitochondrial intermembrane 
space, thereby developing a proton motive force across the mitochondrial intermembrane 
space and the mitochondrial matrix. Once the electrons reach the end of the ETC they bond 
with H+ and O2 to form water. The H+ in the mitochondrial intermembrane space flow 
along their electrochemical gradient into the matrix of the mitochondrion through the F0F1 
ATP synthase. Oxidative phosphorylation can effectively be described by the following 
equation:   





Considering the substrates required for oxidative metabolism to function optimally, 
it is of utmost importance that oxygen delivery to the mitochondrion is maximized in order 
to diminish the reliance on substrate-level phosphorylation, and in doing so attenuating the 
development of muscle fatigue. 
1.2 - V̇O2 Kinetics 
1.2.1 - Measuring V̇O2 
 The ability of the oxidative pathways to respond to exercise can be inferred by 
measuring the rate of whole-body or tissue O2 uptake (V̇O2). Whole-body V̇O2 can be 
estimated through the multiplication of cardiac output (?̇?t) by the difference between the 
arterial O2 content (CaO2) and mixed venous O2 content (Cv̅O2). It extends, then, that 
muscle oxygen uptake (V̇O2m) can be estimated as a product of the blood flow to the muscle 
(?̇?m) and the microvascular arteriole-venule O2 content difference: 
Equation 4: V̇O2m = ?̇?m ∙ (CaO2 – CvO2) 
 
While accurate, directly measuring ?̇?m and CvO2 at the level of the exercising 
muscle is invasive and challenging to implement in exercise protocols. It is for this reason 
that pulmonary V̇O2 (V̇O2p) measurements are preferred for many study designs. With 
protocols involving transient changes in WR, breath-by-breath techniques provide unique 
insight on a participant’s V̇O2p kinetic responses. A mass spectrometer and spirometer can 
be utilized to measure the volume rate of air inspired and expired along with the fraction 
of oxygen in the inspired and expired air to estimate the volume of O2 that is inspired and 





(Grassi et al., 1996), but some level of error is present due to venous blood mixing from 
other areas of the body in addition to distortion of the venous flow signal consequent to 
changing blood flow during the transient. 
1.2.2 - V̇O2p Kinetics 
 With an instantaneous, step-increase in WRs below lactate threshold (θL) there are 
three distinct phases in the V O2p response curve from the initial V̇O2p to the final, higher, 
steady-state V̇O2p (Figure 1). Following the step-increase in WR there is an immediate 
elevation of V̇O2p (Phase I; cardiodynamic phase; Barstow et al., 1990) due to upregulated 
pulmonary perfusion consequent to an increase in ?̇?t (related to vagal withdrawal and an 
increase in venous return), but because of the intervening venous volume between the 
muscle and the lung, the initial increase does not reflect increased O2 extraction at the 
muscle. The V̇O2m response is estimated by the rise (phase II) following the phase I 
response, where mitochondrial adjustment to the change in ATP demand is upregulated in 
activity and Cv̅O2 decreases (widening of the arterial-mixed venous O2 difference; Barstow 
et al., 1990) in addition to the continually increasing ?̇?t and ?̇?m. Phase III of the V̇O2p 
kinetic response is reached once a steady state in V̇O2p is maintained (i.e., a plateau in the 
V̇O2p response). 
 When exercising at constant WRs below θL a linear relationship exists between WR 
and the predicted steady state V O2p (V̇O2p gain). The total V̇O2p at a given time during 
sub-θL exercise can be described by the mono-exponential function: 






where V̇O2p (t) is the value of V̇O2p at a given time (t), V̇O2p BSL is the baseline value prior 
to transition, ΔV̇O2p SS is the increase in V̇O2p amplitude above the baseline value to steady 
state, τ is the time constant of the response (referring to the time where 63% of the kinetic 
response to the new V O2p SS is reached), and TD is the time delay.  
When exercising at WRs above θL but below CP (heavy-intensity domain), steady 
state V̇O2p is greater than what would be predicted through the V̇O2p gain prediction model 
associated with sub-θL WRs. This extraneous V̇O2p represents O2 utilization inefficiency 
in the exercising muscle and is termed the V̇O2p slow component (V̇O2p SC). At constant 
WRs above CP and below maximum V̇O2p (V̇O2p-max; very heavy-intensity domain; VH), 
V̇O2p never reaches a steady state, but continues to elevate until V̇O2p-max is reached or the 
exercise session ends. During supra-θL exercise, V̇O2p can be described using a bi-
exponential function, made up of the aforementioned mono-exponential function with the 
addition of another exponential component: 
Equation 6: V̇O2p (t) = V̇O2p BSL + (ΔV̇O2p SS)(1 – e-(t-TD)/τ) + (ΔV̇O2p SC)(1 – e-(t-TDs)/τs) 
 
where V̇O2p SC, TDs and τs represent the slow component parameters.  
1.3 - Nitrate Supplementation 
1.3.1 - Ingestion and General Circulation 
Nitrate (NO3-) has become a molecule of interest in the literature for its possible 
influence on increased muscle O2 utilization efficiency, enhancement of muscle contractile 
capability, and lowering of blood pressure. Dietary NO3- is most commonly found in root 





2006). Within the literature, placebo (PLAC)-controlled studies most commonly employ 
concentrated beetroot juice (BRJ) for its convenient form factor and consistency between 
samples.  
There are two known pathways by which NO3- is metabolized to form its bioactive, 
fully reduced counterpart, nitric oxide (NO). The endogenous pathway is the L-arginine 
pathway, where NO is formed by nitric oxide synthase (NOS) enzymes present in neurons, 
endothelial cells, and in myocytes (Moncada & Higgs, 1993). Alternatively, NO can be 
produced through NOS-independent means by the enterosalivary pathway (Figure 2). With 
dietary supplementation, facultative anaerobic bacteria can reduce NO3- within food to 
nitrite (NO2-) (McKnight et al., 1997; Weitzberg & Lundberg, 1998; Lundberg et al., 2008; 
Burleigh et al., 2018), the intermediary molecule to the fully reduced equivalent, NO. The 
presence of bacteria in the oral cavity are integral to this reduction process, as antibacterial 
mouthwash severely attenuates the elevation in circulating NO3- and NO2- following 
supplementation (Govoni et al., 2008; Petersson et al., 2009; Burleigh et al., 2018). Once 
swallowed, NO can be formed in the acidic environment of the stomach (Lundberg et al., 
1994). Approximately 95% of any remaining NO3- and NO2- is ingested in the small 
intestine (Bartholomew & Hill, 1984) and enters general circulation. Up to 25% of the 
circulating NO3- can be taken up by the salivary glands (Spiegelhalder, 1976; Lundberg et 
al., 2011), increasing the concentration of salivary NO3- up to 20 times (Lundberg & 
Govoni, 2004). The concentrated NO3- becomes readily available for bacterial reduction in 
the oral cavity, where the cyclical process continues. Within the circulation, the stable NO2- 
molecule can spontaneously reduce to NO in hypoxic environments such as 





Considering the effects of acidity and hypoxia in promoting the reduction of NO3- and NO2- 
to NO, it is possible that the bioavailability of NO in active skeletal muscle and the 
surrounding vascular smooth muscle increases during exercise, as that tissue is in a 
relatively acidic and hypoxic state compared to rest (Weitzberg & Lundberg, 1998).  
1.3.2 - Effect of NO3- Supplementation on Blood Flow, Blood Pressure, and 
Haemoglobin Concentration during Exercise 
In order to maximize oxidative phosphorylation, O2 must be delivered to the 
mitochondrion effectively. With an immediate elevation in ATP demand following a step 
increase in WR, O2 delivery must adjust accordingly. While the muscle can initially extract 
more O2 from the blood, it is not enough to maintain an adequate supply. To compensate, 
?̇?t increases linearly with progressively greater WR (Armstrong & Laughlin, 1985).  
As a sympathetic neuronal response to exercise, norepinephrine is released by 
neurons surrounding the vasculature, which stimulates the constriction of smooth muscle 
through the α-adrenoreceptors to restrict blood flow in inactive tissue (Rosenmeier et al., 
2004). However, the endothelium surrounding exercising muscle, the exercising muscle 
itself, and the erythrocytes flowing through the microvasculature can increase blood flow 
by causing vasodilation locally, overpowering the sympathetic nervous response 
(Rosenmeier et al., 2004). Endothelial cells are capable of inducing vasodilation through 
the production and release of vasoactive substances including nitric oxide (NO). Smooth 
muscle relaxation induced by NO works through the activation of guanylate cyclase inside 
the smooth muscle cell, forming cyclic guanosine 3’,5’ monophosphate (cGMP) from 
guanosine triphosphate (Moncada & Higgs, 1993). Once cGMP is formed, it can act on 





calcium concentration ([Ca2+]) in the cytosol decreases, leading to relaxation of the smooth 
muscle (Weitzberg & Lundberg, 1998; Hellsten et al., 2012). 
Considering the pathway NO can induce vasodilation and the increased rate of NO2- 
to NO reduction under hypoxic conditions (Cosby et al., 2003; Shiva et al., 2007; Lundberg 
et al., 2011), it follows that NO3- supplementation may increase blood flow and elevate O2 
partial pressure (PO2) in exercising muscle microvasculature compared to control and 
placebo models by reducing local vascular resistance, thereby maintaining sufficient O2 
supply to the exercising muscle. Increased blood flow and PO2 have been observed in 
rodent models, particularly in muscles composed primarily of type II muscle fibres 
(Ferguson et al., 2013a, 2015), with some evidence of increased PO2 and blood flow in 
humans (Muggeridge et al., 2014; Richards et al., 2018). However, human observations of 
near-infrared spectroscopy (NIRS)-informed deoxyhaemoglobin [HHb] and total 
haemoglobin [Hbtot] concentration show no significant differences (Breese et al., 2013; 
Kelly et al., 2014; Aucouturier et al., 2015; Bailey et al., 2015), while few show any 
increases in oxyhaemoglobin [O2Hb] (Bailey et al., 2015) in NO3- supplementation groups. 
These results may be surprising given the suggestion of vasodilation in humans (i.e., 
increased blood flow and PO2) shown in other studies (Muggeridge et al., 2013; Richards 
et al., 2018).  
1.3.3 - Effect of NO3- Supplementation on Muscle Force Development 
A reliable method of measuring peripheral muscle fatigue is through involuntary 
electrical stimulation of the skeletal muscle of interest to record decreases in muscle torque 





participant’s voluntary motor recruitment through central command to provide consistent 
signal input prior to and following an exercise protocol.  
With NO3- supplementation, Hernández et al. (2012) reported increased force 
production at low-frequency involuntary stimulation (<60 Hz), but not higher, in muscle 
groups composed primarily of type II muscle fibres in rodents. Within the same study, there 
was no change in muscle force production at any stimulation frequency in the soleus 
muscle, which is comprised primarily of type I muscle fibres. These fibre-specific 
influences by NO3- supplementation are congruent with the literature on the presence of 
greater blood flow and microvascular PO2 in type II-predominant muscle (Ferguson et al., 
2013a, 2015). Increased intracellular calcium concentration ([Ca2+]i)  was reported with 
NO3- supplementation from 20-150 Hz stimulation frequencies, which may have been 
attributable to the reported increase in calsequestrin 1 (CASQ1) and dihydropyridine 
receptor (DHPR) protein expression, elevated sarcoplasmic reticulum [Ca2+], and 
concurrent increase in intracellular [Ca2+]i, leading to enhanced muscle twitch force 
production. A similar relationship in the force-frequency relationship has been replicated 
by others with similar changes in CASQ1 and DHPR protein expression (Ivarsson et al., 
2017). 
Within the human model, NO3- supplementation has been shown to increase peak 
torque production at very low frequencies (10 Hz), but without any changes in calcium 
handling protein expression (Whitfield et al., 2017a). This may be attributable to the 
variation between muscle fibre proportions between participant samples, but also to a 
difficulty in testing fibre-specific effects of NO3-, as the muscle fibre proportion of the 





et al., 1997; Luden et al., 2008). The increase in type II muscle fibre contractility with NO3- 
supplementation (Hernández et al., 2012) may be beneficial in higher-intensity exercise 
bouts, where continual recruitment of larger type II muscle fibres occur with increasing 
exercise duration or during bouts of high-intensity exercise.  
In 2017, Van De Walle and Vukovich (2017) published a meta-analysis to inquire 
the effects of NO3- supplementation on exercise performance with a focus on differences 
in training status.  They found that, overall, there was no change in time-trial performance 
for either trained or recreational athletes. However, constant-power exercise to the limit of 
tolerance (LoT) was significantly longer with NO3- supplementation. Sub-group analysis 
showed the training status of the participants was a significant factor, where highly trained 
athletes did not benefit, but recreationally active participants did. The lack of an effect in 
well-trained individuals could be explained by enhanced NOS protein expression (Green 
et al., 2004), leading to greater basal NO3- concentrations compared to recreationally active 
individuals (Jungersten et al., 1997; Poveda et al., 1997). Higher concentrations of resting 
NO3- and NOS in highly trained participants may reduce the net increase in circulating 
NO2- with NO3- supplementation in comparison to recreational participants, thereby 
lessening the impact that NO3- supplementation may provide on enhanced muscle 
contractility. 
1.3.4 - Effect of NO3- Supplementation on V̇O2p and the Development of the 
V̇O2p Slow Component  
 A meta-analysis conducted by Pawlak-Chaouch et al. (2016) found that, overall, 
NO3- supplementation has no effect on resting V̇O2p or end exercise maximal exercise 





(between θL and CP) constant power exercise had a small decrease in end-exercise V̇O2p. 
Very-heavy intensity (between CP and V̇O2p-max work rate) exercise showed a trend 
towards lower V̇O2p but did not reach statistical significance. Reduced V̇O2p measures 
during moderate-, heavy, and in some cases very heavy-intensity exercise may be 
attributable to the enhanced contractility of skeletal muscle observed at low frequency 
stimulation with NO3- supplementation, where less O2 may be required for ATP 
resynthesis.  
With supra-θL constant-power exercise, the V̇O2p SC phenomenon is observed. 
Some studies observing NO3- supplementation have measured the development of the 
amplitude of the extraneous V̇O2p using time to exhaustion exercise protocols (Bailey et 
al., 2009, 2015; Lansley et al., 2011; Kelly et al., 2013; Wylie et al., 2013; Lowings et al., 
2017). Of those studies, the time to the limit of tolerance was extended by 15-22%. There 
was no change in the V̇O2p amplitude at end-exercise, although some groups have reported 
faster phase II kinetics with NO3- supplementation (Breese et al., 2013; Bailey et al., 2015).   
1.3.5 - Study Rationale 
NO3- supplementation has demonstrated effects on increasing muscle torque 
production at low stimulation frequencies, blood flow, and PO2 in type II muscle fibre-rich 
areas. Additionally, there are data that suggest the development of muscle fatigue may be 
challenged by NO3- supplementation and the rate of V̇O2p SC development slowed. While 
many studies have observed muscle torque production, exercise performance, and V̇O2p 
profiles independently, there remains a lack of literature examining the relations between 
these parameters. We intended to produce a study that would effectively relate these topics 





V̇O2p SC amplitude and concurrent muscle fatigue development during constant power 
exercise in the VH-intensity domain reported by Keir et al. (2016a). Employing dietary 
NO3- supplementation provided a unique opportunity to explore the given relationship and 
increase our understanding of muscle function during exercise. 
Therefore, the purpose of this study was to 1) determine the effect of NO3- 
supplementation on the development of muscle fatigue during VH-intensity constant WR 
exercise; 2) observe the effect of NO3- supplementation on the development of the V̇O2p 
slow component; and 3) observe possible alterations in the slope of the V̇O2p SC-muscle 
fatigue relationship. 
Based on the literature, we hypothesized that: 1) absolute V̇O2p and the V̇O2p SC 
would be attenuated at any given time in NO3--rich BRJ vs NO3--depleted BRJ (PLAC) 
during VH-intensity constant-WR exercise, but the total V̇O2p SC amplitude at the limit of 
tolerance (LoT) would be similar between conditions; 2) the development of the V̇O2p SC 
would be linearly related to electrically stimulated muscle force loss, but the relationship 
will be shifted to the right (i.e., less fatigue for a given V̇O2p SC amplitude) and the slope 
will be attenuated; 3) electrically induced muscle force production would be greater (at 10 
Hz and 50 Hz stimulation torque and the 10 Hz-to-50 Hz ratio) at any given time in BRJ 
vs PLAC, and the rate of fatigue development would be attenuated, but fatigue at the LoT 
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Figure 1. Schematic of a hypothetical V̇O2p profile during a step-increase in work rate 
(WR) from a low intensity constant-WR to a moderate, sub-lactate threshold constant-
WR cycling exercise. The solid grey line represents V̇O2p amplitude. The solid vertical 
reference line represents the onset of the elevated constant-WR step increase. V̇O2p BSL 
represents the V̇O2p amplitude during baseline exercise. V̇O2p SS represents the steady 
state V̇O2p. ΔV̇O2p BSL represents the change in V̇O2p amplitude from baseline exercise 
to the steady state V̇O2p amplitude. TD represents the time delay. τ represents the V̇O2p 
















Figure 2. Schematic of the enterosalivary reduction pathway of dietary nitrate (NO3-) to nitrite (NO2-) and nitric oxide (NO) and the
endogenous L-arginine pathway.  
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Chapter II: Nitrate supplementation does not alter the V̇O2p 
SC-muscle fatigue relationship in recreationally active men 
2.1 - Introduction 
Exercise transitions to a constant work rate (WR) at intensities below an 
individual’s lactate threshold (θL) lead to a steady-state increase in the rate of muscle 
(V̇O2m) and pulmonary O2 uptake (V̇O2p) within 2-3 min (Rossiter, 2011; Poole & Jones, 
2012). Exercise at WRs greater than θL but below critical power (CP) results in the 
appearance of a V̇O2p slow component (V̇O2p SC; i.e., an additional V̇O2p above that 
predicted from the linear sub-θL steady-state V̇O2p-WR relationship) which prolongs the 
time before reaching a V̇O2p steady-state, increases the O2 cost of exercise (i.e., increases 
the V̇O2p/WR) and reduces exercise “efficiency” (Rossiter, 2011; Poole & Jones, 2012). 
With exercise intensities above CP, a V̇O2p steady-state is never achieved as V̇O2p rises 
progressively until maximal V̇O2p (V̇O2p-max) and/or exercise is discontinued (Rossiter, 
2011; Poole & Jones, 2012).  The mechanism for the V̇O2p SC has not been established but 
an increased adenosine triphosphate (ATP) cost of force production, increased O2 cost of 
ATP production, and recruitment of higher order, less oxidatively-efficient type II muscle 
fibres have been implicated, with all contributing to a reduced exercise efficiency, and 
possible increased fatigue development and reduced exercise tolerance (Jones et al., 2011; 
Cannon et al., 2014).  
Cannon et al. (2011) reported muscle fatigue was requisite for the development of 
the V̇O2p SC. In that study, muscle isokinetic peak power (measured at 60, 90 and 120 
revolutions per minute; rpm) was reduced at 3 and 8 min in each of heavy- and very-heavy 





observed between 3 and 8 min despite continued development of a V̇O2p SC throughout this 
period. However, Keir et al. (2016) reported progressive peripheral muscle fatigue 
development (as measured by a reduction in electrically stimulated muscle tetanic torque 
production at 10 Hz and 50 Hz, and in the 10/50 Hz ratio) in association with the 
development of a V̇O2p SC during 18 min cycling at a WR equivalent to ~Δ60% (i.e., the 
WR that is 60% the difference between that associated with θL and V̇O2p-max; within the 
very heavy-intensity domain) with time of exercise. In fact, the loss of electrically induced 
muscle force production over time was related linearly to the rise in the V̇O2p SC suggesting 
a mechanistic link between muscle fatigue development and the appearance and evolution 
of an additional O2 requirement by the fatiguing muscle (i.e., the V̇O2p SC).  
Nitric oxide (NO) is a biologically active signalling molecule involved in several 
physiological processes including oxygenated blood flow (?̇?O2) regulation, calcium (Ca2+) 
handling and muscle contractile function and mitochondrial respiration. The ‘classical’ 
endogenous pathway of NO production involves the oxidation of the amino acid, L-
arginine, to form L-citrulline, in an O2-dependent reaction catalyzed by NO synthase 
(NOS).  An alternate pathway of NO production involves the NOS-independent sequential 
reduction of dietary nitrate (NO3-) to nitrite (NO2-) to NO. With this alternate pathway 
ingestion of NO3- and NO2--rich foodstuffs – in particular, leafy green vegetables (e.g., 
spinach, lettuce, and kale) and root vegetables (e.g., beetroot), in vivo stores of NO3- and 
NO2- contribute to increased production of NO. Specifically, dietary NO3- is reduced in the 
saliva via NO3--reducing oral bacteria and gastrointestinal tract to NO2- which is further 
reduced to NO with remaining NO3- and NO2- absorbed and taken up into the portal and 





hypoxia, as is expected to occur in the active muscle during exercise in the heavy- or very 
heavy-intensity domains, promotes the conversion of NO2- to NO (Weitzberg & Lundberg, 
1998). 
Based on a recent systematic review and meta-analysis, when the outcome from all 
studies were combined, dietary NO3- supplementation was shown to lower steady-state 
V̇O2p (Pawlak-Chaouch et al., 2016).  When studies were analyzed based on intensity-
domains, NO3- supplementation tended to lower steady-state V̇O2p in the moderate- and 
heavy-intensity exercise domains but did not consistently attenuate the development of the 
V̇O2p SC in the very heavy-/severe-intensity domain, or resting V̇O2p (Pawlak-Chaouch et 
al., 2016). Of those that had found differences with very heavy-/severe-intensity exercise, 
dietary NO3- supplementation was associated with greater exercise tolerance, reduced end-
exercise V̇O2p SC amplitude, and/or reduced end-exercise V̇O2p, with no change in the 
overall kinetics for V̇O2p adjustment (Bailey et al., 2009, 2010a, 2010b; Lansley et al., 
2011).   
In rats, NO3--rich beetroot juice supplementation (BRJ) was associated with 
increased total hindlimb and muscle blood flow (?̇?m), vascular conductance (Ferguson et 
al., 2013a), and microvascular oxygen partial pressure (PO2; Ferguson et al., 2015) during 
treadmill running or electrically induced twitch contractions, especially in those muscles 
composed primarily of type II muscle fibres.  Additionally, the kinetics of the fall in 
microvascular PO2 was slower with BRJ supplementation consistent with a higher ?̇?O2 and 
microvascular ?̇?O2-to-local muscle V̇O2 (V̇O2m; Ferguson et al., 2013b).  These data, in 
combination, suggest that BRJ supplementation improves muscle O2 delivery and raises 





to- and in steady-state exercise, with the effect being manifest to a greater extent in muscle 
composed predominantly of type II fibres (Jones et al., 2016). In humans, there are few 
studies examining the effects of NO3- supplementation on muscle blood during exercise. 
Richards et al. (2018) reported an increase in forearm blood flow following 12.8 mmol 
NO3- consumption via BRJ due to vasodilation. Cosby et al. (2003) also observed a 
significant increase in forearm blood flow with sodium nitrite infusion (36 µM) at rest and 
during exercise. Near-infrared spectroscopy (NIRS) provides information on local muscle 
microvascular concentrations of oxy- ([O2Hb]), deoxy- ([HHb]), and total haemoglobin 
([HbTot]), and haemoglobin saturation (% O2 saturation), with [HHb] reflecting the local 
?̇?O2/V̇O2m. In studies where NIRS was used in combination with NO3- supplementation, 
NO3- effects on muscle oxygenation have not been consistently observed (Bailey et al., 
2009, 2015; Breese et al., 2013; Kelly et al., 2014; Patterson et al., 2014), which may be 
surprising given the NO3--induced lowering of O2 cost of exercise (and improved 
efficiency) in humans and improved microvascular blood flow and O2 delivery reported in 
rats. 
Dietary NO3- supplementation has been shown to increase mean power output in 
short duration (lasting 6s) all-out sprints (Wylie et al., 2016) and extend the time to reach 
the limit of tolerance (LoT) during constant-power exercise (Bailey et al., 2010a; Kelly et 
al., 2014). At the muscle level, improved performance following NO3- supplementation 
could be related to attenuated rates of muscle force and power loss, especially at lower 
stimulation frequencies (Hernández et al., 2012; Haider & Folland, 2014; Coggan et al., 
2015; Whitfield et al., 2017a).  Improved force development with NO3- supplementation 





increased intracellular [Ca2+] (Hernández et al., 2012; Pironti et al., 2016), which may 
attenuate the loss in force production with prolonged exercise.   
Given the observed beneficial effects of NO3- supplementation on improving 
exercise economy (lower O2 cost of exercise), muscle force production (especially at lower 
stimulation frequencies), and muscle microvascular O2 delivery and ?̇?O2/V̇O2, especially 
in type II muscle fibres which are expected to be recruited during exercise in the very 
heavy-intensity domain, an intervention employing NO3- supplementation provides an 
opportunity to better examine potential mechanistic links between the development of 
peripheral muscle fatigue and V̇O2p slow component during constant-WR exercise within 
the very heavy-intensity domain that was reported previously by Keir et al. (2016a).  The 
purpose of this study was to examine the relationship between muscle force production and 
the V̇O2p SC during very heavy-intensity exercise with and without dietary NO3- 
supplementation (in the form of NO3--rich BRJ). We tested the hypotheses that: 1)  absolute 
V̇O2p and the V̇O2p SC would be attenuated at any given time in NO3--rich BRJ vs NO3--
depleted BRJ (placebo; PLAC), but the total V̇O2p SC amplitude at the LoT would be similar 
between conditions; 2) the development of the V̇O2p SC would be related linearly to 
electrically stimulated muscle force loss, but the relationship would be shifted to the right 
(i.e., less fatigue for a given V̇O2p SC amplitude) and the slope would be attenuated; 3)  
electrically induced muscle force production would be greater (at 10 Hz and 50 Hz 
stimulation torque and the 10/50 Hz ratio) at any given time in BRJ vs PLAC, and the rate 
of fatigue development would be attenuated, but fatigue at the LoT would be similar 






2.2 - Methods 
2.2.1 - Participants 
Healthy young adult males (n=8; age 24 ± 2 yr [mean ± SD]; body mass 82 ± 8.5 
kg; height 179 ± 7 cm; V̇O2p max 43.8 ± 6.0 ml • kg-1 • min-1) volunteered for the study. The 
participants were highly active (minimum of 3 strenuous exercise sessions per week 
involving activities such as ice hockey, soccer, racquet sports, or regular gym attendance 
involving a mixture of resistance and endurance exercise). All participants were non-
smokers with no known metabolic, cardiovascular, neurological, respiratory, or 
musculoskeletal conditions, and were not taking any medications.  
2.2.2 - Ethical Approval 
The study was conducted according to the Declaration of Helsinki and all 
procedures were approved by The University of Western Ontario Ethics Committee for 
Research on Human Subjects. Procedures and risks were explained to each participant 
verbally and in writing. Participation was voluntary and all participants provided informed 
written consent following review of the letter of information and completion of the Physical 
Activity Readiness Questionnaire for Everyone (PAR-Q+) form prior to being admitted 
into the study. 
2.2.3 - Experimental Protocol 
The study was carried out using a double-blind, block-randomized, repeated 







2.2.4 - Exercise Testing 
On the initial visit to the laboratory, participants performed a ramp incremental 
(RI)–sprint (SP) exercise test (RISP) on an electronically-braked cycle ergometer 
(Velotron, RacerMate Inc. Seattle, WA) to determine peak V̇O2p, estimated θL, respiratory 
compensation point (RCP) (see 2.2.9 - Data Analysis, paragraph 4), and critical power 
(CP). The RISP test consisted of 6 min baseline (BSL) exercise at 25 W, RI exercise (25 
W•min-1) to the limit of tolerance (LoT). Participants were instructed to maintain a steady 
cadence in the range of 70-90 revolutions per minute (rpm) and continue for as long as 
possible. The RI test ended after the participants could not maintain a minimum cadence 
of 60 rpm despite strong verbal encouragement. Following the RI test, the participants had 
3 min recovery (2.67 min cycling with no load [i.e., 0 W], 0.33 min pre-SP at 20 W), and 
a 3 min SP test with a resistance of 6.25% body mass (Figure 3) . The recovery period was 
required to change the Velotron control program from a controlled constant work rate (WR) 
to a controlled resistance, variable WR mode. Prior to the SP test, participants were 
instructed to pedal as quickly as possible until they were informed the test was complete. 
They were not provided any time points and were given strong verbal encouragement 
throughout the test. For the RI test, the participants were unable to view any data on the 
computer monitor apart from their cadence. For the SP test, the computer monitor was 
turned off and the participants were unable to view the time or cadence. The examiners 
were able to view the time and cadence on another, smaller monitor directed away from 
the participant. The efficacy of the RISP protocol in estimating CP was outlined by 





Constant-WR familiarisation rides to the LoT were conducted following the initial 
RISP test (48 hr recovery between rides) primarily to establish a WR which enabled 
participants to tolerate constant-power exercise for a limit of 18 min and secondarily to 
develop a constant WR-time duration estimation of CP. The initial ride was completed at 
a WR 10% higher than CP estimated by the preliminary RISP (RISPprelim) exercise, and 
the WR for subsequent trials was adjusted until participants could tolerate the exercise only 
to a limit of 18 min. Linear regression of the work rate and inverse of exercise duration 
was used to estimate CP and contrast against the estimation provided by the SP test.  
Following the familiarisation rides, participants were randomly assigned to one of 
two conditions; nitrate-rich beetroot juice supplement (BRJ; ~6.4 mmol nitrate per 70 mL 
“shot”; Beet It; James White Drinks, Ipswich, United Kingdom) or nitrate-depleted BRJ 
supplement (PLAC; ~0.04 mmol nitrate per 70 mL “shot”; Beet It, James White Drinks, 
Ipswich, United Kingdom). Both conditions began with a pre-supplementation RISP test, 
followed by a 5 d loading phase where participants consumed 2 BRJ “shots” per day; one 
with breakfast and the other with dinner. The participants were instructed to refrain from 
using antibacterial mouthwash (or other antibacterial-containing oral products) throughout 
the supplementation phases to maximise plasma NO3- and NO2- concentration, as the 
presence of commensal bacteria (specifically, active nitrate reductases) in the oral cavity 
are necessary for reducing NO3- to NO2-, the precursor to NO in the NOS-independent NO3-
-NO2--NO pathway (Jones et al., 2018). Participants were instructed to not consume 
alcohol at least 24 prior to each test and caffeine 12 hours prior. They were also provided 
a list of common foods that are high in NO3-/NO2- content and were requested to avoid 





provided a list of foods of low/medium/high glycemic index and were asked to avoid high-
index foods prior to testing to maintain a steady blood glucose concentration between 
exercises and conditions.  
Participants completed a pre-supplementation RISP test on day 1, after which 
participants began a 5 d “loading” phase (days 1-5) to elevate plasma [NO3-] and [NO2-]. 
Constant-WR testing for each condition began on day 6 of supplementation with a recovery 
day separating each test day (Figure 4). On alternating days 6-18 of supplementation, a 
total of 7 constant-WR exercises were conducted per condition. Six constant-WR tests were 
performed at an intensity within the very heavy-intensity (VH) domain with exercise 
durations randomly assigned to last 3, 8, 13, 18 min (VH3, VH8, VH13, VH18, 
respectively), and to the LoT. The constant-WR exercise durations were chosen to establish 
a time-course for the development of the V̇O2p SC and loss of muscle force production 
consequent to the VH exercise. Two additional 18 min exercise bouts were completed on 
separate days; a second VH18 bout with NIRS-derived measures of the quadriceps muscle 
oxy-/deoxygenation (see 2.2.5 - Data Collection, paragraph 2), and one 18 min exercise 
bout performed at a WR corresponding to the V̇O2p at ~80% of the estimated θL V̇O2p 
(moderate-intensity, MOD). Each constant-WR trial began with 6 min BSL cycling at 50 
Watts (W) followed by a step-increase in WR to the specified MOD- or VH-intensity and 
specified duration. For the LoT trial exercise was continued until the subject was unable to 
maintain a cadence of 60 rpm, despite strong verbal encouragement. Participants were 
instructed to consume one bottle of BRJ 1-2 hours prior to each exercise bout, as that time 





values (Wylie et al., 2013). Participants continued to consume 2 BRJ bottles per day 
throughout each of the 20 d supplementation regimes. 
Prior to and following each constant-WR trial volitional and electrically induced 
leg muscle torque and power were measured to assess the effect of VH intensity exercise 
on peripheral muscle fatigue development (see 2.2.6 - Neuromuscular Testing). On day 20, 
participants completed a final RISP exercise test. At the completion of the first condition, 
the participants completed a 10-14 d “washout” phase to allow plasma concentrations of 
nitrate ([NO3-]) and nitrite ([NO2-]) to return to baseline (non-supplemented) levels (Curtis 
et al., 2015). The participants repeated the protocol following the washout period under the 
opposite BRJ supplement. 
2.2.5 - Data Collection 
Participants wore a nose-clip and breathed through a mouthpiece for breath-by-
breath gas exchange measurements. The inspired and expired air flow and volumes were 
measured by a low dead-space (100 mL) bidirectional turbine (VMM 110; Alpha 
Technologies, Laguna Hills, CA, USA) and pneumotach (model 4813; Hans Rudolph, 
Shawnee, KS, USA). Respired air was sampled and fractional concentrations of O2 and 
carbon dioxide (CO2) were analyzed continuously by mass spectrometry (AMIS 2000; 
Innovision, Lindvedvej, Denmark). Prior to each test the pneumotach was adjusted for zero 
flow, and the volume turbine was calibrated by using a syringe of known volume (3.003 
L) over a range of flow rates. The time delay between an instantaneous, square wave 
change in fractional gas concentration at the sampling inlet and its detection by the mass 
spectrometer was measured electronically by a computer. Precision-analysed gas mixtures 





concentrations were recorded in real time and time-aligned at a sampling rate of 100 Hz to 
provide a profile of each breath. The algorithms of Swanson (1980) were employed to 
calculate alveolar gas exchange on a breath-by-breath basis. End-tidal CO2 and O2 
pressures (PETO2; PETCO2) were detected using a peak-detection algorithm on a computer 
and inspired and expired volumes and durations were used to produce a profile of each 
breath. 
 Local muscle oxy-/deoxygenation of the quadriceps vastus lateralis muscle of the 
left leg was measured using frequency-domain, multi-distance near-infrared spectroscopy 
(NIRS; Oxiplex TS. Model 92505, ISS; Champaign, IL, USA) as described by Keir et al. 
(2016b). The NIRS system consisted of a single channel of eight laser diodes at two 
wavelengths (λ = 690 nm and 828 nm; four at each wavelength) that were pulsed in rapid 
succession down a photomultiplier tube. A NIRS probe (connected to the laser diodes and 
photomultiplier tube by optical fibres) consisted of two parallel rows of light-emitter fibres 
and a single detector fibre bundle. For each wavelength, the source-detector separations 
were 2.0, 2.5, 3.0, and 3.5 cm. The probe was placed on the centremost point of the belly 
of the vastus lateralis muscle, and measurements were collected continuously at 1000 Hz 
data acquisition frequency for the entire duration of one of the two VH18 rides for each 
participant within each condition. Prior to each test, the NIRS was calibrated after an 
instrument warm-up of at least 20 min as recommended by the manufacturer. 
 During the MOD and VH18 (NIRS) trials, blood was drawn from the hyperemic 
earlobe at select timepoints (BSL, 3, 8, 13, 18 min following the step exercise transition) 
and analysed immediately for lactate concentration using a Lactate Scout (Sports Resource 





prior to each supplementation phase (day 1 of supplementation prior to ingestion), on day 
1 of the experimental phase (day 6 of supplementation), midway through the experimental 
phase (day 14 of supplementation), and on the last day of the experimental phase (day 20 
of supplementation). Within 2 min of collection, blood samples were centrifuged and 
plasma removed and stored frozen at -80C for later analysis of plasma [NO3-] and [NO2-] 
as described by Cox (1980). Blood pressure was measured at rest, BSL (VH and MOD), 
and end-exercise (MOD only) using a Welch Allyn Flexiport sphygmomanometer on the 
upper arm and a Littmann Cardiology III stethoscope. Heart rate (HR) was measured 
continuously using a Polar Transmitter (Polar Electro, Lachine, QC, Canada) and recorded 
(PowerLab Chart, v 7.3.1; ADInstruments, Colorado Springs, CO, USA). 
2.2.6 - Neuromuscular Testing 
Prior to and following each RISP and constant-WR test (with exception to VH NIRS), 
neuromuscular testing was completed to assess peripheral muscle fatigue. Muscle fatigue 
was inferred through changes in isometric torque and peak isotonic knee-extension velocity 
and torque production using voluntary and electrically stimulated involuntary muscle 
contractions. Post-exercise testing began in the laboratory next to the cardiorespiratory 
laboratory  35 s after the end of each exercise bout (Figure 5).  
Participants completed voluntary and involuntary isometric and voluntary isotonic 
knee extension contractions with the left leg while seated in a Humac-Norm Cybex 
dynamometer (Computer Sports Medicine, Stoughton, MA), with the hip and ankle joints 
maintained at 90. The backrest of the seat was adjusted to maintain a proper hip joint 
angle, with shoulder and waist belts securing the participants. The knee joint angle was 90 





isotonic knee extension repetition. The ergometer’s lever arm axis of rotation was aligned 
with the axis of rotation of the participant’s knee. The resistance pads at the ankle were 
adjusted to rest comfortably on the participant’s legs proximal to the malleoli. Two 
aluminum foil electrodes (~20 x 5 cm) were wrapped in soaked paper towel with a 
conductive brine and taped securely to the knee extensor musculature. One electrode was 
placed ~7 cm superior to the patella, and the other electrode was placed over the proximal 
1/3 of the anterior thigh ~10 cm distal to the inguinal fold. The electrodes were connected 
to a constant current muscle stimulator (DS7AH; Digitimer, Welwyn Garden City, 
Hertfordshire, UK) to produce involuntary contractions. Torque and peak isotonic knee 
extension velocity was collected and displayed on a computer using Spike 2 version 7.02 
(Cambridge Electronic Design, Cambridge, UK) at a frequency of 500 Hz. 
2.2.7 - Isometric Measures 
 Doublet involuntary activation was elicited to establish maximal knee-extensor 
twitch torque (200 µs square wave pulse width; 400 V; range 270-575 mA). Maximal knee 
extensor twitch torque was defined as the point at which knee extensor torque production 
did not increase despite increases in stimulation intensity. Two maximum voluntary 
contractions (MVCs) lasting 3 s were completed with 2 min rest separating each 
contraction. A third MVC was conducted if the first two differed by >10%. Throughout 
each MVC participants were given strong verbal encouragement. Within each MVC, a 
superimposed singlet contraction followed by a potentiated singlet contraction was elicited 
to calculate voluntary activation:  






where VA represents voluntary activation (%), SIT is the superimposed twitch torque 
(Newton-metres; Nm), and PST is the potentiated singlet twitch torque (Nm).  
Involuntary tetanic stimulation of the quadriceps muscle was completed at 
frequencies of 10 Hz and 50 Hz for 1 s (50 µs square wave pulse width; 400 V; range 230-
620 mA) at a current which elicited 50% torque production of MVC with 50 Hz frequency 
(Figure 6). Each involuntary stimulation was separated by 5 s. Post-exercise stimulation 
current intensities were identical to the pre-exercise values for each test day. 
2.2.8 - Isotonic Measures 
 Peak isotonic knee extension velocity and torque were measured following the 
isometric contractions in pre- and post-exercise testing. Peak isotonic knee extension 
velocity was measured with a resistance of 20% of the pre-exercise MVC torque production 
value. Three maximal knee extensions were performed with 2 s between each kick, and 
participants received strong verbal encouragement to contract as rapidly as possible. Limb 
velocity was recorded in deg/s. The product of peak angular velocity (rad/s) and peak 
torque (Nm) was used to calculate peak isotonic power (WRpeak). 
2.2.9 - Data Analysis 
 Using Origin version 2018 (OriginLab, Northampton, MA, USA), breath-by-breath 
V̇O2p data from all individual trails were edited by removing aberrant data that laid more 
than 3 SD from the local mean. Remaining breath-by-breath data were linearly interpolated 
on a second-by-second basis, ensemble-averaged, and time-aligned, where time “zero” 
represents the start of the exercise to the higher WR. Phase II (fundamental) V̇O2p kinetics 





Equation 5: V̇O2p(t) = V̇O2p BSL + (∆V̇O2p SS)(1 - e-(t-TD/τ) 
 
where V̇O2p(t) represents the value of V̇O2p at any given time of the step exercise transition, 
V̇O2p BSL is the BSL V̇O2p prior to transition, ∆V̇O2p SS is the change in V̇O2p to reach steady 
state above the BSL value, τ is the time constant of the response, and TD is the time delay. 
The phase I-II transition point and the onset of the V̇O2p SC were established using the 
criteria outlined by Rossiter et al. (2002). The V̇O2p at the 3, 8, 13, and 18-min time points 
and at the LoT was measured using 20 s of 5 s bin-averaged data. The method employed 
for determining the phase I-II transition was repeated for the phase II-III transition point. 
Once established, the 20 s bin-averaged V̇O2p at that time point was determined to be the 
beginning of the V̇O2p SC. The V̇O2p SC amplitude at the 3, 8, 13, and 18-min time points 
and the LoT was determined by the difference between the V̇O2p at that time and the V̇O2p 
at which phase III was determined to begin (Figure 7).  
NIRS-derived muscle [HHb], [O2Hb], and [HbTot] at BSL (i.e., 6 min exercise 
period prior to step-increase in WR) were determined using 30 s of data; 15 s pre-3 min 
and 15 s post-3 min. The 3 min time point was chosen as BSL exercise steady-state 
conditions were met as determined by HR and V̇O2p. Averages calculated at the 3, 8, and 
13 min post-step increase time points were similarly measured using 30 s of data at each 
time point, with 15 s prior to and following the respective time point. The 18 min time 
point averages were calculated using the final 30 s leading up to 18 min. HR data was 
collected at 1 Hz acquisition frequency, and averages were calculated in an identical 





 Gas exchange data collected from ramp increment tests were examined by 3 
reviewers with expertise in reviewing gas exchange data to determine θL and RCP for each 
participant. The estimated θL was determined where the rate of CO2 output (V̇CO2p) 
increased disproportionately from V̇O2p, with an increase in the ventilation (V̇E)-to-V̇O2p 
slope and PETO2, and where V̇E/V̇CO2p and PETCO2 remained stable. RCP was 
determined as the point where isocapnic conditions were no longer maintained, but rather 
was accompanied by a decrease in PETCO2 and a further increase in the slope of V̇E/V̇CO2 
against V̇O2p. 
 Muscle fatigue was inferred through decreases in torque production with voluntary 
(peak MVC torque, VA, and peak isotonic power) and involuntary measures (peak torque 
produced in potentiated singlet twitch, 10 Hz and 50 Hz tetanic contractions, and 10/50 Hz 
torque production ratios) post-exercise compared to pre-exercise in absolute and relative 
terms. Muscle fatigue measurements at the 3, 8, 13, and 18-min time points were compared 
with the V̇O2p SC amplitude in absolute and relative terms to examine changes to the 
relationship between peripheral muscle fatigue and the development of the V̇O2p SC with 
nitrate supplementation. 
2.2.10 - Statistical Analysis 
 All data are presented as mean ± SD. A two-way repeated measure analysis of 
variance (ANOVA) was used to compare select variables across time points and 
supplementation conditions. Where significant differences were found, a Tukey’s post-hoc 
analysis was performed for multiple comparisons testing. Paired t-tests were used to 
compare differences in variables between the VH18 and MOD exercise conditions. A 





fatigue development and the V̇O2p SC amplitude and % reserve while controlling for 
repeated measures within the same subjects. The slopes of the V̇O2p SC amplitude and % 
reserve versus muscle torque production loss correlations were compared using a multiple 
linear regression test for the evaluation of equality of regression slopes. All statistical 
analyses were performed using SigmaPlot version 14.0 (Systat Software, San Jose, CA). 
Statistical significance was accepted at P < 0.05. 
2.3 - Results 
2.3.1 - Plasma Nitrate, Nitrite Concentration 
Group mean plasma [NO3-] and [NO2-] data are displayed in Figure 8. The pre-
supplementation plasma [NO3-] and [NO2-] were not different (P > 0.05) between PLAC 
and BRJ, but were collectively elevated (P < 0.05) on days 6, 14, and 20 of BRJ 
supplementation (NO3- 32 ± 14 µM at BSL to 325 ± 143 µM; NO2- 119 ± 130 nM at BSL 
to 245 ± 155 nM).   
2.3.2 - WRpeak-RI, CP, V̇O2p-max, HRmax, θL, and RCP 
The group mean peak WR from RISPprelim (WRpeak-RI) was 334 ± 56 W. The group 
mean estimated CP via constant power-time duration regression analysis from the 
familiarisation rides was 225 ± 48 W. The corresponding mean V̇O2p-max was 3.58 ± 0.58 
L·min-1 (43.8 ± 6.0 mL·kg·min-1) and maximum HR (HRmax) 187 ± 7 beats·min-1 (bpm; 95 
± 3 % of the age-predicted HRmax. The V̇O2p corresponding to the θL and RCP was 2.05 ± 
0.56 L·min-1 and 2.93 ± 0.73 L·min-1, respectively. No differences were found amongst the 
RISP-determined V̇O2p-max values nor in RISP-estimated θL or RCP between either 
condition or pre- or post-supplementation. The WR assigned to MOD (80% LT) and VH 





2.3.3 - Moderate-Intensity Constant-WR V̇O2p, HR, BP, and Blood Lactate 
During MOD exercise, BRJ V̇O2p increased (P < 0.001) from 1.09 ± 0.07 L•min-1 
at BSL to 1.54 ± 0.41 L•min-1 at 3 min with no further change to 18 min; the V̇O2p response 
was similar in BRJ and PLAC throughout exercise (Figure 9). The moderate-intensity end-
exercise V̇O2p values were 77 ± 4% and 79 ± 7% θL in BRJ and PLAC, respectively.  
BRJ HR (Figure 10) increased (P < 0.001) from BSL (90 ± 10 bpm) to 3 min (102 
± 13 bpm), with no further change throughout exercise, representing 57 ± 6% of RISPprelim 
HRmax; HR was similar between BRJ and PLAC throughout exercise. There was no effect 
of NO3- supplementation on systolic, diastolic, or mean arterial blood pressure at rest, BSL, 
or end-exercise in MOD (Table 1). Blood lactate concentration (Figure 11) showed no 
change from BSL to end-exercise, indicating the participants exercised in the moderate-
intensity domain (i.e., sub-θL). 
2.3.4 - Very Heavy-Intensity Constant-WR V̇O2p, V̇O2p SC, HR, Blood 
Lactate, and NIRS 
During VH exercise, BRJ V̇O2p increased (P < 0.001) from 1.14 ± 0.13 L•min-1 at 
BSL to 3.38 ± 0.69 L•min-1 at 18 min, representing 94 ± 5 % V̇O2p-max; the V̇O2p response 
was similar in BRJ and PLAC throughout exercise. The projected phase II V̇O2p SS was 
similar between conditions (BRJ, 2.90 ± 0.64 L•min-1; PLAC, 2.96 ± 0.63 L•min-1); the 
onset of the V̇O2p SC was similar between conditions (BRJ, 137 ± 37 s; PLAC, 149 ± 31 s). 
The BRJ V̇O2p SC amplitude increased (P < 0.001) from 129 ± 108 mL•min-1 at 3 min to 
419 ± 145, 503 ± 114, 498 ± 143, and 549 ± 215 mL•min-1 at 8, 13, 18 mins, and the LoT, 





reserve. The development of the V̇O2p SC (absolute amplitude and % reserve) was not 
different at any time point between BRJ and PLAC (Figure 13a). 
BRJ HR increased (P < 0.001) from BSL (93 ± 9) to 18 min (179 ± 6 bpm), 
representing 98 ± 3 % HRmax; HR was similar between conditions. The time to the LoT 
was not different between the conditions (BRJ, 23.8 ± 5.6 min; PLAC, 22.6 ± 5.5 min; P = 
0.621). BRJ blood lactate increased (P < 0.001) from BSL (1.9 ± 0.4 L•min-1) to VH18 
(11.8 ± 0.3 L•min-1). The rise in blood lactate concentration at BSL and throughout exercise 
was similar between conditions. Group mean NIRS-derived haemoglobin concentration 
data from the VH18 NIRS exercise are displayed in Figure 12. BRJ group mean [HHb] 
increased (P < 0.001) from BSL (22 ± 8 µM) to 3 min (31 ± 15 µM) with no further change 
throughout the exercise (34 ± 18 µM at 18 min); [HHb] was similar in BRJ and PLAC 
throughout exercise. BRJ [O2Hb] decreased (P < 0.02) from BSL ( 50 ± 15 µM) to 3 min 
(46 ± 12 µM) with no further change throughout the exercise; [O2Hb] was similar (P > 
0.05) between BRJ and PLAC except for 13 min, where BRJ was lower (P < 0.05; BRJ, 43 
± 10 µM; PLAC, 51 ± 15 µM). BRJ [HbTot] increased (P = 0.001) from BSL (71 ± 22 µM) 
to 3 min (77 ± 27 µM) but did not change throughout the exercise to 18 min (78 ± 27 µM); 
[HbTot] was similar in BRJ and PLAC throughout the exercise. BRJ Hb O2 % saturation 
decreased (P < 0.001) from BSL (70 ± 4 %) to 3 min (62 ± 6), with no further change 
throughout the exercise; Hb O2 % saturation was similar between BRJ and PLAC 
throughout the exercise. 
2.3.5 - Neuromuscular Fatigue Measures - Baseline Values 
 The pre- and post-exercise neuromuscular torque and power measures are 





any of the pre-exercise measures across all exercise trials within and across each 
supplementation condition (P > 0.05). Overall, voluntary quadriceps muscle activation 
(VA) was similar in PLAC and BRJ and remained unchanged compared to BSL following 
VH (or MOD) exercise, except for the percent drop from BSL in VH8 (P < 0.05; BRJ, -4 
± 6 % BSL; PLAC 2 ± 5 % BSL). 
2.3.6 - Neuromuscular Fatigue Measures - Moderate-Intensity Constant-WR 
There was no change in WRpeak or MVC torque production consequent to MOD 
exercise. The BRJ 10 Hz electrically stimulated quadriceps muscle contraction torque was 
reduced (P < 0.001) after MOD exercise (46 ± 12 Nm) compared to BSL (61 ± 11 Nm) but 
was not different from PLAC (40 ± 8 Nm). The 50 Hz torque production remained at BSL 
levels, leading to a reduced (P < 0.001) 10/50 Hz torque production ratio following MOD 
exercise (0.36 ± 0.07) compared to BSL (0.44 ± 0.08), and was similar to PLAC. BRJ 1 
Hz electrically stimulated torque production was lower (P < 0.001) following MOD 
exercise (52 ± 13 Nm) compared to BSL (61 ± 13) and was similar to PLAC. No other 
variables were different from BSL values, and there were no differences following MOD 
exercise values between BRJ and PLAC for any other variables. 
2.3.7 - Neuromuscular Fatigue Measures - Very Heavy-Intensity Constant-
WR 
There was a decrease (P < 0.05) in BRJ WRpeak from 3 min (855 ± 131 W) to the 
LoT (701 ± 157 W); BRJ and PLAC WRpeak were similar throughout the exercise. MVC 
torque production decreased (P < 0.01) from 3 min (253 ± 47 Nm) to the LoT (208 ± 44 
Nm); BRJ and PLAC MVC were similar throughout the exercise. BRJ MVC torque 





with a subsequent decrease (P < 0.05) to the LoT (208 ± 44 Nm). At VH13, MVC torque 
production BRJ was higher (P < 0.01) than PLAC (217 ± 35 Nm), but not at any other 
time point.  
10 Hz peak torque production decreased (P < 0.001) from VH3 (43 ± 9 Nm) to 
VH18 (27 ± 12 Nm) within both conditions without further change to the LoT. PLAC 10 
Hz peak torque production did not change between VH13 and the LoT. BRJ and PLAC 10 
Hz torque production were similar throughout the exercise. BRJ 50 Hz torque did not 
decrease throughout the exercise. There were no differences between BSL and PLAC apart 
from VH18 (BRJ, 111 ± 32 Nm; PLAC, 88 ± 21 Nm; P < 0.01). As a result of the decrease 
in 10 Hz but not 50 Hz torque production over time, the 10/50 Hz torque ratio was also 
reduced with time. The BRJ 10/50 Hz ratio decreased (P < 0.001) from VH3 (0.37 ± 0.05) 
to VH18 (0.24 ± 0.07), with no further change to the LoT (0.21 ± 0.05); the BRJ and PLAC 
10/50 Hz ratios were similar throughout the exercise. Figure 13 displays the changes in 
involuntary stimulated contraction isometric torque at 10 and 50 Hz frequencies (B), and 
MVC and 10/50 Hz ratio (C) with time and between conditions in VH exercise. 
2.3.8 - V̇O2p Slow Component and Peripheral Muscle Fatigue 
 The rise in V̇O2p SC amplitude and fall in 10 Hz electrically stimulated torque 
production (inferred by percent drop in torque production) were not linearly correlated (P 
> 0.05, r2 = 0.06) in BRJ but were in PLAC (P < 0.05, r2 = 0.12). The V̇O2p SC % reserve 
and 10 Hz fatigue was not linearly correlated in BRJ (P > 0.05, r2 = 0.09 was in PLAC (P 
< 0.05, r2 = 0.12). The linear correlation of V̇O2p SC amplitude and 50 Hz involuntary 
stimulation fatigue was not significant in BRJ or PLAC. The V̇O2p SC % reserve and 50 Hz 





= 0.09). The V̇O2p SC amplitude and the 10/50 Hz torque ratio percent drop was linearly 
correlated (Figure 14) in BRJ (P < 0.001, r2 = 0.28) and PLAC (P < 0.001, r2 = 0.32). 
Similarly, the V̇O2p SC % reserve and 10/50 Hz torque ratio percent drop was linearly 
correlated in BRJ (r2 = 0.23, P < 0.002) and PLAC (r2 = 0.44, P < 0.0001). The slopes of 
the linear correlations of the V̇O2p SC amplitude and the 10/50 Hz torque production ratio 
were not different from one another (BRJ, slope = 6.85 (mL/min)/(10/50 Hz ratio); 
PLAC, slope = 8.34 (mL/min)/(10/50 Hz ratio); P = 0.628). The Y-intercepts (Y-int) 
were also not different from one another (BRJ, Y-int = 161.04 mL•min-1; PLAC, Y-int 
62.00 mL•min-1; P = 0.385) Similarly, the slopes of the linear correlations of the V̇O2p SC 
% reserve and the 10/50 Hz torque production ratio were not different from one another 
(BRJ, slope = 0.75 (% V̇O2p SC  reserve)/(10/50 Hz ratio; PLAC, slope = 1.16 (% V̇O2p 
SC reserve)/(10/50 Hz ratio); P = 0.215). The Y-int were also not different between 








Table 1. Blood pressure at rest, baseline exercise, and end-exercise with placebo and nitrate supplementation during moderate 
intensity exercise. 
 BRJ PLAC 
 Rest BSL End Exercise Rest BSL End Exercise 
SBP, mmHg 121 ± 6 129 ± 6* 137 ± 9* 127 ± 8 134 ± 6 137 ± 6* 
DBP, mmHg 80 ± 7 76 ± 3 75 ± 6 76 ± 5 76 ± 5 77 ± 5 
MAP, mmHg 93 ± 6 93 ± 3 96 ± 6 93 ± 4 96 ± 3 97 ± 3 
Values are mean ± SD. BRJ, nitrate supplementation; PLAC, placebo supplementation; BSL, baseline exercise; SBP, systolic blood 
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Figure 3. A ramp-increment sprint test (RISP; A) and sprint-only portion of RISP test (B) of a representative participant. White circles 
represent V̇O2p (left Y axis). The black line represents power output (WR; right Y axis). The dashed vertical line in figure A represents 
the onset of the RISP test. Baseline power output was at 25 W, and the RI slope was 25 W•min-1. Following the end of the RI portion of 
the test, participants rested for 2:40 min at a WR of 0 W while a computer program was switched to conduct the SP test. After 2:40 min, 









Figure 4. Schematic of the exercise protocol. All rides involved pre- and post-exercise neuromuscular (NM) fatigue testing apart from 
one 18 min ride that employed near-infrared spectroscopy (NIRS). RISP, ramp increment-sprint exercise; PLAC, placebo 










































































Figure 6. Pre- and post-exercise torque comparisons of a representative participant from the VH18 exercise protocol. (A) Maximum 
voluntary contraction (MVC), and involuntary electrical stimulation at 50 Hz (B) and 10 Hz (C) frequencies. The first depression in the 
MVC demonstration is a singlet involuntary stimulation. The second, larger depression in the MVC demonstration is a doublet 































Figure 7. Profile of the rate of pulmonary oxygen uptake (V̇O2p) in a representative 
participant from baseline exercise (BSL) to the limit of tolerance (LoT) during constant-
power very heavy intensity exercise. The black line represents the V̇O2p response after 
removal of data points lying more than 3 standard deviations away from the local mean 
and 5 s ensemble averaging. The black line centered closely around the grey horizontal 
reference line at 0.0 L•min-1 represents the residuals of the fit. The dashed grey horizontal 
reference line at 2.9 L•min-1 represents the projected phase II steady state V̇O2p (V̇O2p SS) 
to the end of exercise. The grey horizontal reference line at 2.6 L•min-1 represents the onset 
of the V̇O2p slow component (V̇O2p SC; Phase III, beginning at 88 s). The grey horizontal 
reference line at 3.3 L•min-1 represents V̇O2p-max. The V̇O2p SC magnitude was calculated as 
the difference between the V̇O2p amplitudes at the 3, 8, 13, 18-minute, and LoT time points 
and the onset of the V̇O2p SC. The V̇O2p SC percent reserve was calculated as the amplitude 
difference between V̇O2p-max and V̇O2p SC onset at the 3, 8, 13, 18-minute, and LoT time 
points. 
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Figure 8. Blood nitrate (A) and nitrite (B) concentration on days 1, 6, 14, and 20 of 
supplementation. Black lines represent nitrate supplementation (BRJ); grey lines represent 
placebo supplementation (PLAC). No supplementation was ingested prior to the blood 
draw on day 1 for either condition. (*) difference (P < 0.05) from PLAC. (†) difference (P 


































Figure 9. Group mean rate of oxygen uptake (V̇O2p) for nitrate (BRJ) and placebo 
supplementation (PLAC) during moderate- and very heavy-intensity exercise. Error bars 
at the baseline (BSL), 3, 8, 13, 18-minute time points and the limit of tolerance (LoT) 
represent standard deviation. Black bars represent BRJ; grey bars represent PLAC. Black 
circles are very heavy-intensity BRJ data; grey circles are very heavy-intensity PLAC data. 
Black triangles are very heavy-intensity data with BRJ. Grey triangles are moderate-
intensity data with PLAC. The solid vertical reference line represents the onset of the 
exercise transition. The dashed horizontal lines represent the group mean V̇O2p associated 
with V̇O2p-max, respiratory compensation point (RCP), and lactate threshold (θL). (*) 
difference (P < 0.05) from previous. (†) difference (P < 0.05) from 18 min. (‡) difference 
(P < 0.05) from LoT. (¥) difference (P < 0.05) from moderate-intensity exercise. 
Time (min)
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Figure 10. Group mean heart rate data for nitrate supplementation (BRJ) and placebo 
supplementation (PLAC) during moderate- and very heavy-intensity exercise. Error bars 
at baseline (BSL), 3, 8, 13, 18-minute time points and the limit of tolerance (LoT) represent 
standard deviation. Negative error bars represent BRJ; positive error bars represent PLAC. 
Black circles are very heavy-intensity BRJ data; grey circles are very heavy-intensity
PLAC data. Black triangles are very moderate-intensity BRJ data; grey triangles are 
moderate-intensity PLAC data. The solid vertical reference line represents the onset of the 
exercise transition. The dashed horizontal reference line represents the maximum heart rate 
(HRmax) from the preliminary ramp increment-sprint (RISP) test. (*) difference (P < 0.05)
from the previous measure. (†) difference (P < 0.05) from 18 min. (‡) difference (P < 0.05)
from LoT.   
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Figure 11. Blood lactate concentration during moderate and very heavy intensity exercise 
with nitrate (BRJ) and placebo (PLAC) supplementation. Error bars at baseline (BSL), 3, 
8, 13, 18-minute time points and the limit of tolerance (LoT) represent standard deviation.
Positive error bars represent the BRJ conditions; negative error bars represent PLAC. 
Black circles are very heavy-intensity BRJ data; grey circles are very heavy-intensity 
PLAC data. Black triangles are very moderate-intensity BRJ data; grey triangles are 
moderate-intensity PLAC data. The solid vertical reference line represents the onset of 
the exercise transition. (*) difference (P < 0.05) from previous. (†) difference (P < 0.05) 
from 18 min. 
Time (min)




























































Figure 12. NIRS-derived muscle microvascular concentration of oxy- ([O2Hb]), deoxy-
([HHb]), and total haemoglobin ([HbTot]). Error bars at baseline (BSL), 3, 8, 13, and 18
min time points represent standard deviation. Black error bars represent BRJ; grey error 
bars represent PLAC. Black circles represent BRJ [HbTot]; grey circles represent PLAC 
[HbTot]. Black triangles represent BRJ [O2Hb]; grey triangles represent PLAC [O2Hb].
Black squares represent BRJ [HHb]; grey squares represent PLAC [HHb]. The solid 
vertical reference line represents the onset of the exercise transition. (*) difference (P < 
0.05) from previous. (†) difference (P < 0.05) from 18 min. 
Time (min)
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Figure 13.  (A) V̇O2p sc % reserve, (B) 10 and 50 Hz peak isometric torque, and (C) MVC 
and 10/50 Hz peak isometric torque ratio during very heavy intensity exercise with nitrate 
(BRJ) and placebo (PLAC) supplementation. Error bars at baseline (BSL), 3, 8, 13, 18 min 
and the limit of tolerance (LoT) represent standard deviation. Black error bars represent
BRJ; grey error bars represent PLAC. In graph A, black circles represent BRJ data; grey 
circles represent PLAC data. In graph B, black triangles represent BRJ 10 Hz torque 
production; grey triangles represent PLAC 10 Hz torque production. Black circles 
represent BRJ 50 Hz torque production; grey circles represent PLAC 50 Hz torque 
production. In graph C, black circles represent BRJ MVC torque production; grey circles 
represent PLAC MVC torque production. Black triangles represent BRJ 10/50 Hz torque 
production ratio; grey triangles represent PLAC 10/50 Hz torque production ratio. (*) 
difference (P < 0.05) from previous. (†) difference (P < 0.05) from 18 min. (‡) difference 


















































































r2 = 0.28, P < 0.001
y = 6.85x+161.04
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r2 = 0.23, P < 0.002
y = 0.7520x+31.31
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Figure 14. The relationship between the V̇O2p slow component (SC) amplitude with nitrate (BRJ; A) and placebo (PLAC; B)
supplementation, V̇O2p SC  % reserve with BRJ (C) and PLAC (D) supplementation and 10/50 Hz involuntary stimulation torque ratio 
after 3, 8, 13, and 18 min of very heavy-intensity constant-power output exercise (VH3, VH8, VH13, and VH18), and limit of tolerance 
(LoT). Black triangles represent VH3; white triangles represent VH8; black circles represent VH13; white circles represent VH18; black 






2.4 - Discussion 
The effects of dietary NO3- supplementation on V̇O2p, V̇O2p SC, and loss of 
voluntary and electrically stimulated quadriceps muscle torque and power development 
(i.e., fatigue), and the time to volitional fatigue during very heavy-intensity (VH) constant-
WR leg cycling exercise have been studied individually, but there has not yet been inquiry 
to the role of NO3- supplementation on their collective contributions to the linear V̇O2p SC-
muscle fatigue development relationship. Therefore, the current study explored whether 
dietary NO3- supplementation would affect these parameters (and subsequently) the linear 
V̇O2p SC-muscle fatigue development relationship, with muscle fatigue inferred through 
voluntary (MVC) and involuntary (1, 10, 50 Hz electrical-stimulation) torque production 
loss measures during constant-WR stationary cycling exercise of varying duration. The 
main findings were: (1) 20 days NO3- supplementation (via beetroot juice) significantly 
elevated plasma [NO3-] and [NO2-] throughout the protocol; (2) the V̇O2p SC developed 
coincident with muscle fatigue, as inferred through the decrease in MVC torque 
production, 10 and 50 Hz involuntary stimulation torque production, and the 10/50 Hz 
torque production loss ratio; (3) the greatest increase in V̇O2p SC amplitude and increase in 
muscle fatigue was coincident with the duration of VH-intensity constant-WR exercise; (4) 
despite the coincident development of the V̇O2p SC and muscle fatigue with duration of VH-
intensity constant-WR exercise, dietary NO3- supplementation did not affect steady-state 
V̇O2p, the V̇O2p SC and its development, the loss of quadriceps muscle torque and power 
production, or the relationship between the development of the V̇O2p SC and loss of muscle 
torque production; and (5) exercise tolerance during VH intensity exercise was not affected 






between the temporal development of muscle fatigue and the increasing V̇O2p SC 
amplitude during VH-intensity constant-WR exercise that has been reported previously 
(Keir et al., 2016a).   
Consistent with other studies employing concentrated NO3- supplementation via 
BRJ (Vanhatalo et al., 2010; Larsen et al., 2011; Wylie et al., 2013), plasma [NO3-] and 
[NO2-] were elevated throughout 20 days of supplementation but remained at lower 
baseline concentrations with nitrate-depleted BRJ placebo supplementation (PLAC).  In 
addition, plasma [NO3-] and [NO2-] prior to beginning BRJ supplementation were equal to 
the plasma concentrations measured during the PLAC supplementation, thereby 
confirming the effectiveness of the PLAC supplement as a placebo intervention and also 
demonstrating that the 14 d washout period was sufficient to return [NO3-] and [NO2-] to 
pre-supplement levels. While consuming two “shots” of nitrate-rich BRJ concentrate daily 
with each containing 6.4 mmol NO3-, our participants developed a collective ~900 % 
increase in plasma [NO3-] from 32 ± 14 µM at BSL to 325 ± 143 µM and a ~100 % increase 
in plasma [NO2-] from 119 ± 130 nM at BSL to 245 ± 155 nM. 
The elevation in plasma [NO3-] and [NO2-] are similar to previous studies involving 
similar ingestion protocols of dietary BRJ supplementation (Larsen et al., 2007, 2010), but 
may be considered to be lower than average within the literature, where most have found 
post-supplementation plasma [NO3-] and [NO2-] in the range of 400-600 µM and 350-450 
nM, respectively (Vanhatalo et al., 2010; Breese et al., 2013; Wylie et al., 2016). Of note, 
in two participants, compared to PLAC, the increase in plasma [NO2-] was lower (< 2-fold) 






was higher (5-fold) and similar amongst all participants, suggesting, possibly, a 
diminished conversion of NO3- to NO2- in these two participants. We attribute the 
somewhat attenuated [NO3-] and [NO2-] elevation response to the time point and bolus 
volume/mass which the participants consumed the BRJ supplements prior to the blood 
sampling procedure. Plasma [NO3-] and subsequent [NO2-] at the time of collection are 
dependent partially on the mass of NO3- consumed and the time delay to plasma collection. 
Wylie et al. (2013) conducted a pharmacokinetic and dose-response analysis of dietary 
NO3- supplementation via BRJ and found the greatest elevations of plasma [NO3-] and 
[NO2-] occurred at approximately 2- and 4-hours post-ingestion, respectively. Our 
participants were instructed to consume one “shot” of the supplement (~6.4 mmol) 1-2 
hrs prior to their scheduled exercise. Typically, the participants had their blood drawn 
approximately 30 minutes prior to exercise. The participants may have consumed at a time 
point within an hour of blood sampling where scheduling conflicts required the exercise to 
be ~1-2 hours post-blood sampling, leading to an artificially lowered [NO3-] and [NO2-] 
than that which would be measured immediately prior to exercise. Additionally, ingestion 
of a greater mass of supplementation is also correlated with higher plasma [NO3-] and 
[NO2-] in a dose-dependent manner (Wylie et al., 2013). These trends have been 
corroborated by others, with [NO3-] and [NO2-] being significantly elevated (approximately 
650 µM, 700 nM; NO3- and NO2-, respectively) compared to the concentrations in the 
current study (approximately 300 µM and 200 nM; NO3- and NO2-, respectively) occurring 
with 12.8 mmol [NO3-] ingestion 2.5 hours pre-collection (Tillin et al., 2018). 
In the present study, continuous exercise muscle fatigue testing was not possible 






multiple exercises were conducted of specific duration (3, 8, 13, 18 minutes, and the LoT) 
to effectively compare the fatigue measures between the supplementation conditions. With 
VH-intensity constant-WR exercise, the 10 and 50 Hz electrically stimulated quadriceps 
muscle torque production decreased with time. In the present study the decrease in 
voluntary and electrically stimulated torque production was similar in PLAC and BRJ, 
except at 18 min where torque production associated with 50 Hz stimulation was higher in 
BRJ. The overall lack of effect of NO3- supplementation muscle torque production conflicts 
with our hypothesis that the decrease in muscle force development would be attenuated at 
specific times following VH intensity exercise. Previous studies examining the effect of 
NO3- supplementation on electrically stimulated muscle torque production found greater 
torque production in non-fatigued muscle at low frequency (<20 Hz) stimulations in 
humans (Whitfield et al., 2017b). Hernández et al. (2012) reported that following nitrate 
feeding, electrically stimulated force production was greater in isolated rat fast-twitch, but 
not in slow-twitch, muscle at stimulation frequencies 1-50 Hz. With exercise in the VH-
intensity domain (supra-CP), there is a progressively greater recruitment of motor units 
containing type II muscle fibres (Saunders et al., 2000; Osborne & Schneider, 2006). 
Therefore, in the present study it was hypothesized that with VH-intensity exercise, dietary 
NO3- supplementation would attenuate the loss of muscle force production. The lack of an 
attenuated decrease in muscle force production with continued exercise may be due to the 
equal type I-II muscle fibre representation within the quadriceps muscle group. For 
example, the vastus lateralis muscle is composed of approximately 50% type I and 50% 
type II muscle fibres (Taylor et al., 1997; Luden et al., 2008). In the present study, measures 






within 35 s after exercise was stopped to accommodate the transfer from the cycle 
ergometer to the neuromuscular testing apparatus. Although some recovery from fatigue 
may have occurred during the short transfer (Froyd et al., 2013), significant quadriceps 
muscle fatigue remained. However, the transfer time and the specific times of post-exercise 
neuromuscular measure assessment initiation were identical after each of the exercise trials 
and in the PLAC and BRJ conditions and so are unlikely to have influenced measurements 
of muscle torque/power. 
A greater decrease of electrically stimulated muscle torque production at low (10 
Hz) relative to higher stimulation frequencies (50 Hz), and the 10/50 Hz  stimulation torque 
production ratio, is an indicator of peripheral muscle fatigue due to alterations in 
mechanisms that occur at or beyond the neuromuscular junction (Jones, 1996; Allen et al., 
2008). In the present study, the absolute V̇O2p and V̇O2p SC amplitude profiles and the 
reduction in the 10/50 Hz stimulation ratio were not altered following dietary NO3- 
supplementation in VH exercise at any time point. The V̇O2p SC amplitude and the 10/50 
Hz stimulation ratio were also related with no difference between conditions. The similar 
V̇O2p during VH exercise in BRJ and PLAC contrasts with some (Larsen et al., 2007, 2011; 
Bailey et al., 2010a; Lansley et al., 2011), but not all (Boorsma et al., 2014; Thompson et 
al., 2014), studies examining the effects of dietary NO3- supplementation on O2 economy. 
In contrast to the similar V̇O2p SC seen between conditions in the present study, an 
attenuated V̇O2p SC following dietary NO3- supplementation has been reported by others 
(Bailey et al., 2009; Breese et al., 2017). Keir et al. (2016) reported a linear relationship 
between the V̇O2p SC amplitude and muscle fatigue. In the current study, the evolution of 






PLAC conditions (r2 = 0.28 and 0.32, respectively, P < 0.001), with the slopes of linear 
regressions, 6.85 (mL/min)/(10/50 Hz ratio) (BRJ) and 8.34 (mL/min)/(10/50 Hz 
ratio) (PLAC), not different between conditions (P = 0.628).  
Although differences in V̇O2p or in VH exercise were not observed in the present 
study, previous studies have proposed mechanisms by which O2 utilization efficiency may 
increase with NO3- supplementation, with a resultant lowering of V̇O2m (and subsequently 
V̇O2p) for an identical constant-WR exercise. Larsen et al. (2011) examined the effect of 
sodium nitrate on mitochondrial respiration in the healthy male human vastus lateralis 
muscle. They found an increase in ATP formed per O2 molecule (higher P/O2) utilized in 
addition to an increase in total ATP production, attributable to a decrease in H+ leak across 
the inner mitochondrial membrane and an associated downregulation of uncoupling protein 
3 (UCP-3) and adenine nucleotide translocase (ANT) proteins following NO3- 
supplementation. However, the downregulation of UCP-3 and ANT proteins following 
dietary NO3- supplementation remains controversial, as Whitfield et al. (2016) found no 
alteration to the expression of these proteins in human vastus lateralis muscle. To our 
knowledge, the examination of these proteins following NO3- supplementation have not 
been studied further. In addition to possible enhanced O2 utilization efficiency, others have 
suggested a decrease in ATP cost of force production, therefore reducing the O2 cost of 
exercise. Bailey et al. (2010a) examined changes in absolute PCr, Pi, ADP, and ATP using 
phosphorus-31 magnetic resonance spectroscopy. They found a reduction in estimated 
ATP production coincident with reduced V̇O2p during constant-WR moderate- and VH-






mitochondrial O2 utilization efficiency, but rather through a reduced ATP cost of force 
production.  
The lack of a clear cause of lowered V̇O2p and V̇O2p SC found in some studies but 
not others make the assessment in the current study difficult to rationalise. Within the 
literature some groups have commented on the presence of “responders” and “non-
responders” to dietary NO3- supplementation via beetroot juice (Christensen et al., 2013; 
Boorsma et al., 2014). In the current study, 6 out of 8 participants had an increase in plasma 
[NO2-] in excess of 2.0 times BSL concentration, with one individual at 6.13 times BSL 
concentration. The two participants slightly below 2.0 times BSL concentration had a 
concurrent 5.2 and 4.5 times increase in [NO3-] compared to BSL concentration, indicating 
that these two individuals did not effectively convert the dietary NO3- to NO2-. Of the six 
participants with a [NO2-] elevation twice above BSL measures, one had a significantly 
attenuated V̇O2p SC amplitude % reserve following the VH18 exercise trial with dietary 
NO3- supplementation (66 vs. 87 % reserve; BRJ vs. PLAC) in addition to a significantly 
longer time to the LoT (24.5 vs. 19.6 min; BRJ vs. PLAC). This individual also showed a 
notable decrease in both systolic and diastolic blood pressures at rest (BRJ, 111/64; PLAC, 
120/72; systolic/diastolic) and during 50 W BSL cycling exercise (BRJ, 114/65; PLAC, 
134/69; systolic/diastolic). Based on the characteristics of this individual, there is no 
apparent reason why they would show significant physiological responses where others did 
not. While other groups have found similar notable exceptions within their study groups, 
there remains a gap in the literature examining the differences between participants within 






A possible secondary (adverse) outcome to the multiple RISP and VH-intensity 
exercise trials used in the present study was a “training”-induced increase in aerobic fitness 
of the participants which might serve to complicate the interpretation of the findings. 
However, when comparing peak V̇O2p values for each of the components of RISP testing 
and at the end of the longer duration VH-intensity constant power trials performed 
throughout the BRJ and PLAC protocols, no systematic improvement in V̇O2p-max, θL, RCP, 
or CP were found suggesting that there was no change in the fitness level of the 
participants.  
2.5 - Assumptions and Limitations 
Several assumptions made to the measures involved in the present study: (1) the 
participants adhered to the dietary and supplementation schedule requests; (2) the change 
in V̇O2p being a representative measure of the change in V̇O2m; (3) the time delay in post-
exercise fatigue measures were consistent between conditions within each participants to 
allow for direct comparison. 
There are several limitations within the measures involved in the present study. The 
sample size of the current study was limited to 8 participants. The participants were block-
randomised, meaning the participants were set into groups of two, in the order that they 
gave consent for the study, and were randomly assigned into the BRJ or PLAC conditions 
for the first condition to offset the risk of a training effect that could overshadow the effects 
of dietary NO3- supplementation resultant from having a majority of the participants begin 
the study in one condition. To further diminish the probability of a training effect from 






constant-WR exercise tests to find their final work rate. It was our goal to find a proper 
WR for the duration of the study whilst maximising the participants’ fitness level prior to 
the onset of either intervention to ensure any changes in V̇O2p-max, θL, or RCP were resultant 
of the dietary NO3- supplementation and not due to an increase in general fitness.  
While the participants were regularly inquired in regards to their dietary habits and 
continually reminded of foods to avoid, it was assumed that the participants adhered to the 
dietary requests (i.e., reduced consumption of NO3--rich foodstuffs) and followed the 
provided supplementation schedule (i.e., one bottle with breakfast, one with dinner, with 
one of them consumed approximately 1-2 hours prior to exercise). While the plasma [NO3-
] and [NO2-] are somewhat lowered compared to other studies, their consistency across the 
full protocol period of 20 days within each condition indicate that the schedules were 
indeed followed.  
At the completion of each exercise trial, participants removed themselves from the 
cycle ergometer and transferred to the neuromuscular physiology laboratory next to the 
cardiorespiratory physiology laboratory. The time delay from the cessation of exercise to 
the start of the first muscle fatigue test was limited to approximately 35 s for both group 
conditions, but it may be assumed that some muscle fatigue recovery may have been 
accomplished. Despite this time delay, significant muscle fatigue was present (inferred by 
1, 10, 50 Hz involuntary electrical-stimulation, MVCs, and isotonic knee extension) within 
each condition with 3 min of VH-intensity constant-WR exercise, with progressively 
greater muscle fatigue during the 8, 13, and 18 min-duration exercises, and the LoT. 
Additionally, the neuromuscular fatigue measures were repeated at 5- and 10- min post-






significantly depressed compared to the pre-exercise measures. While attempts were made 
to adequately match the biomechanics of the stationary cycle ergometer to the upright 
seated ergometer used during the neuromuscular assessment protocol (i.e., matching of 
joint angles), some level of error in the muscle fatigue measures and their relation to the 
V̇O2p SC with the contributions of whole-limb exercise in stationary cycling versus the 
isolated quadriceps testing may be present. 
2.6 - Future Directions 
The current study examined the effects of NO3- supplementation on the relationship 
of the development of the V̇O2p SC and muscle fatigue inferred by the 10/50 Hz ratio loss 
in torque production, with side measures of NIRS-informed [HHb], [O2Hb], and [HbTot]. 
Similar investigations should be performed with a greater number of participants with 
concurrent electromyography recordings and immediate post-exercise neuromuscular 
fatigue examination. Additionally, muscle biopsies should be conducted to expand the 
limited body of literature examining alterations to [Pi], [ATP/ADP], and Ca2+-handling 
protein expression following dietary NO3- supplementation to determine alterations in 
metabolic activity and contractility in fatigued muscle. Finally, the increasing suggestion 
of the presence of “responders” and “non-responders” in the literature should be addressed 
to understand why specific individuals within a given group (e.g., recreationally active 









2.7 - Conclusions 
 Despite a significant elevation in plasma [NO3-] and [NO2-] throughout 20 days of 
NO3- supplementation, the current study found no effect of NO3- supplementation and its 
subsequent reduction to NO2- and the bioactive NO molecule on the development of the 
V̇O2p SC amplitude, muscle fatigue, or the V̇O2p SC-muscle fatigue relationship. The V̇O2p 
SC developed with time, as did muscle fatigue inferred through the decrease in MVC torque 
production, 10 and 50 Hz involuntary electrical stimulation torque production, and the 
10/50 Hz involuntary electrical stimulation torque production ratio. Muscle fatigue was not 
altered by dietary NO3- supplementation at the LoT, and the duration to the LoT was no 
different between conditions. The mechanisms determining the interactions between the 
reduction of NO2- to provide enhanced NO bioavailability are complex, and the 
mechanisms through which dietary NO3- supplementation may affect muscle contractility 
and O2 utilization are even more so. 
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Appendix I: Averaged Data 
Table 2.  Blood plasma nitrate and nitrite concentration on day 1, 6, 14, and 20 of placebo and nitrate supplementation.  
 BRJ PLAC 
 Day 1 Day 6 Day 14 Day 20 Day 1 Day 6 Day 14 Day 20 
Plasma Nitrate, 
µM 





208 ± 114 * 334 ± 220 * 192 ± 63 * 83 ± 51 95 ± 59 80 ± 24 102 ± 48 
Values are mean ± SD. BRJ, nitrate supplementation; PLAC, placebo supplementation; M, micromolar concentration; nM; 














Table 3. Group-averaged maximum rate of oxygen uptake, lactate threshold, respiratory compensation point, critical power, and peak 
work rate from ramp incremental-sprint exercises.  
   BRJ PLAC 
 Prelim Pre Post Pre Post 
V̇O2p-max, L•min-1 3.58 ± 0.58 3.70 ± 0.66 3.66 ± 0.63 3.58 ± 0.61 3.57 ± 0.67 
θL, L•min-1  2.05 ± 0.56 2.00 ± 0.55 2.10 ± 0.50 1.90 ± 0.50 2.00 ± 0.52 
RCP, L•min-1 2.93 ± 0.73 2.92 ± 0.71 3.07 ± 0.63 2.86 ± 0.65 3.00 ± 0.67 
Values are mean ± SD. BRJ, nitrate supplementation; PLAC, placebo supplementation; Prelim, preliminary; Pre, pre-supplementation, 
day 1; Post, post-supplementation, day 20; L•min-1, litres per minute.  
 
 
Table 4. Group-averaged estimated critical power and peak work rate from ramp incremental-sprint and preliminary constant-work 
rate familiarisation exercises. 
    BRJ PLAC 
 Lin Reg Prelim Pre Post Pre Post 
CP, W 225 ± 48 210 ± 54 243 ± 63 * 252 ± 57 *† 239 ± 65 * 252 ± 64 *† 
WRpeak-RI, W N/A 333 ± 60 338 ± 63 340 ± 62 335 ± 67 337 ± 58 
Values are mean ± SD. BRJ, nitrate supplementation; PLAC, placebo supplementation; Lin Reg, linear regression value of preliminary 
constant-work rate familiarisation exercises; Prelim, preliminary ramp incremental-sprint; Pre, pre-supplementation, day 1; Post, post-
supplementation, day 20; CP, critical power; WRpeak-RI, peak work rate from ramp-incremental exercise; W, watts. (†) difference (P < 



















Values are mean ± SD. BRJ, nitrate supplementation; PLAC, placebo supplementation; BSL, baseline exercise; LoT, limit of 
tolerance; VH3/8/13/18, very heavy-intensity exercise at the 3, 8, 13, and 18-minute time points; L•min-1, litres per minute; bpm, beats 
per minute; mmol, millimole. (*) difference (P < 0.05) from previous. (∂) difference (P < 0.05) from baseline. (†) difference (P < 0.05) 









 BSL - BRJ BSL - PLAC 3 min - BRJ 3 min - PLAC 8 min - BRJ 8 min - PLAC 
V̇O2p, L•min-1 1.09 ± 0.07 † 1.09 ± 0.12 † 1.54 ± 0.41 *∂ 1.52 ± 0.31 *∂ 1.55 ± 0.40 ∂ 1.50 ± 0.36 ∂ 
HR, bpm 90 ± 10 † 88 ± 16 † 102 ± 13 *∂ 102 ± 13 *∂† 105 ± 12 ∂ 103 ± 15 ∂† 
La-, mmol 1.66 ± 0.44 1.91 ± 0.30 1.95 ± 0.31 1.79 ± 0.43 1.88 ± 0.42 1.91 ± 0.43 
 13 min - BRJ 13 min - PLAC 18 min - BRJ 18 min - PLAC 
V̇O2p, L•min-1 1.54 ± 0.40 ∂ 1.54 ± 0.34 ∂ 1.57 ± 0.40 ∂ 1.59 ± 0.33 ∂ 
HR, bpm 103 ± 13 ∂ 103 ± 15∂ † 106 ± 12 ∂ 111 ± 14 *∂ 






Table 6. Very heavy-intensity constant work-rate rate of oxygen uptake, rate of oxygen uptake slow component amplitude, rate of 
oxygen uptake slow component percent reserve, heart rate, and blood lactate concentration. 
 
Values are mean ± SD. BRJ, nitrate supplementation; PLAC, placebo supplementation; BSL, baseline exercise; LoT, limit of 
tolerance; VH3/8/13/18, very heavy-intensity exercise at the 3, 8, 13, and 18-minute time points; L•min-1, litres per minute; bpm, beats 
per minute; mmol, millimole. (*) difference (P < 0.05) from previous. (∂) difference (P < 0.05) from baseline. (†) difference (P < 0.05) 





 BSL - PLAC BSL - BRJ VH3 - PLAC VH3 - BRJ VH8 - PLAC VH8 - BRJ 
V̇O2p, L•min-1 1.14 ± 0.13 †‡ 1.15 ± 0.11 †‡ 3.06 ± 0.67 *∂ 3.06 ± 0.60 *∂ 3.33 ± 0.70 ∂ 3.34 ± 0.60 ∂ 
V̇O2p SC, mL•min-1 N/A N/A 129 ± 108 †‡ 82 ± 88 †‡ 419 ± 145 * 383 ± 132 * 
V̇O2p SC  Res, % N/A N/A 18 ± 15 ‡ 11 ± 11 ‡ 60 ± 15 * 58 ± 8 * 
HR, bpm 93 ± 9 †‡ 95 ± 9 †‡ 154 ± 5 *∂†‡ 155 ± 5 *∂†‡ 170 ± 6 *∂†‡ 170 ± 7 *∂†‡ 
La-, mmol 1.9 ± 0.4 † 1.8 ± 0.3 † 5.6 ± 0.6 *∂† 5.9 ± 1.1 *∂† 9.6 ± 1.4 *∂† 8.7 ± 1.4 *∂† 
 VH13 - PLAC VH13 - BRJ VH18 - PLAC VH18 - BRJ LoT - PLAC LoT - BRJ 
V̇O2p, L•min-1 3.36 ± 0.63 ∂ 3.40 ± 0.56 ∂ 3.38 ± 0.69 ∂ 3.40 ± 0.57 ∂ 3.38 ± 0.70 ∂ 3.38 ± 0.60 ∂ 
V̇O2p SC, mL•min-
1 
503 ± 114 436 ± 156 498 ± 143 471 ± 181 549 ± 215 510 ± 261 
V̇O2p SC  Res, % 69 ± 5 65 ± 7 72 ± 10 71 ± 17 77 ± 22 71 ± 26 
HR, bpm 176 ± 5 ∂‡ 176 ± 7 ∂‡ 179 ± 6 ∂ 179 ± 6 ∂ 182 ± 7 ∂ 184 ± 9 ∂ 







Table 7. Oxyhaemoglobin, deoxyhaemoglobin, and total haemoglobin concentration in the vastus lateralis muscle with placebo and  









Values are mean ± SD. BRJ, nitrate supplementation; PLAC, placebo supplementation; BSL, baseline exercise; VH3/8/13/18, very 
heavy-intensity exercise at the 3, 8, 13, and 18-minute time points; Hb O2 % Sat, haemoglobin oxygen percent saturation; HbTot, total 
haemoglobin concentration; HHb, deoxyhaemoglobin concentration; O2Hb, oxyhaemoglobin concentration; µM, micromolar 
concentration. (*) difference (P < 0.05) from previous. (∂) difference (P < 0.05) from baseline. (†) difference (P < 0.05) from 18 minutes. 




BSL - BRJ BSL - PLAC VH3 - BRJ VH3 - PLAC 8VH - BRJ VH8 - PLAC 
Hb O2 % Sat 70 ± 4 † 72 ± 5 † 62 ± 6 *∂† 64 ± 5 *∂† 60 ± 8 ∂ 62 ± 5 ∂ 
HbTot (µM) 71 ± 22 † 76 ± 22 † 77 ± 27 *∂ 82 ± 25 *∂ 77 ± 26 ∂ 83 ± 25 ∂ 
HHb (µM) 22 ± 8 † 21 ± 7 † 31 ± 15 *∂† 30 ± 11 *∂ 33 ± 18 ∂ 33 ± 11 ∂ 
O2Hb (µM) 50 ± 15 † 55 ± 16 † 46 ± 12 *∂ 52 ± 15 45 ± 10 ∂ 51 ± 15 ∂ 
 VH13 - BRJ VH13 - PLAC VH18 - BRJ VH18 - PLAC 
Hb O2 % Sat 58 ± 8 ∂ 61 ± 5 ∂ 58 ± 8 ∂ 60 ± 5 ∂ 
HbTot (µM) 78 ± 27 ∂ 84 ± 25 ∂ 78 ± 27 ∂ 84 ± 25 ∂ 
HHb (µM) 34 ± 18 ∂ 34 ± 11 ∂ 34 ± 18 ∂ 34 ± 11 ∂ 






Table 8. Pre-exercise baseline and post-exercise neuromuscular fatigue measures from moderate and very heavy intensity exercise 







 BSL - BRJ BSL - PLAC VH3 - BRJ VH3 - PLAC VH8 - BRJ VH8 - PLAC VH13 - BRJ VH13 - PLAC 
MVC, Nm 280 ± 51 280 ± 36 253 ± 47 ‡ 259 ± 32 †‡ 249 ± 46 ‡ 247 ± 39 ∂‡ 248 ± 63 ∂‡¥ 217 ± 35 ∂ 
MVC % BSL   -8 ± 10 †‡ -11 ± 5 †‡ -13 ± 5 ‡ -15 ± 11 ‡ -14 ± 11 ‡ -22 ± 10 
10 Hz, Nm 61 ± 11 62 ± 10 43 ± 9 ∂†‡ 41 ± 7 ∂†‡ 33 ± 10 ∂‡ 35 ± 8 ∂†‡ 31 ± 14 ∂ 29 ± 9 ∂ 
10 Hz % BSL   -31 ± 7 †‡ -35 ± 6 †‡ -43 ± 12 ‡ -44 ± 10 †‡ -46 ± 18 ‡ -52 ± 10 
50 Hz, Nm 140 ± 27 142 ± 21 117 ± 23 113 ± 14 ∂ 115 ± 26 ∂ 126 ± 13 †‡ 115 ± 28 108 ± 16 ∂ 
50 Hz % BSL   -15 ± 6 -20 ± 8 -19 ± 14 -14 ± 4 † -18 ± 17 -22 ± 8 
10/50 Hz Ratio 0.44 ± 0.08 0.44 ± 0.05 0.37 ± 0.05 ∂†‡ 0.37 ± 0.05 ∂†‡ 0.29 ± 0.05 
*∂‡ 
0.28 ± 0.06 *∂ 0.27 ± 0.07 ∂ 0.26 ± 0.06 ∂ 
10/50 Hz %BSL   -19 ± 9 †‡ -19 ± 5 †‡ -30 ± 6 †‡ -35 ± 11 ‡ -35 ± 13 ‡ -38 ± 13 
1 Hz, Nm 61 ± 13 63 ± 16 46 ± 9 ‡ 46 ± 12 ∂† 43 ± 12 ∂ 42 ± 11 ∂ 43 ± 13 ∂ 38 ± 12 ∂ 
1 Hz %BSL   -18 ± 6 †‡ -26 ± 7 †‡ -29 ± 7 -33 ± 12 -31 ± 16 -36 ± 9 
PST, Nm 75 ± 14 77 ± 18 66 ± 11 70 ± 14 †‡ 64 ± 16 65 ± 14 62 ± 17 56 ± 15 
PST % BSL   -7 ± 13 †‡ -11 ± 7 † -13 ± 10 ‡ -19 ± 10 -17 ± 18 -21 ± 18 
VA, % 90 ± 6 90 ± 6 91 ± 6 88 ± 4 87 ± 4 90 ± 4 90 ± 5 87 ± 7 
VA % BSL   2 ± 7 -3 ± 5 -4 ± 6 ¥ 2 ± 5 1 ± 5 -3 ± 3 
WRpeak, W 891 ± 122 898 ± 186 855 ± 131 ‡ 898 ± 183 †‡ 829 ± 161 809 ± 190 810 ± 175 811 ± 212 







Table 8 (continued). Pre-exercise baseline and post-exercise neuromuscular fatigue measures from moderate and very heavy intensity 




 BSL - BRJ BSL - PLAC VH18 - BRJ VH18 - PLAC LoT - BRJ LoT - PLAC MOD - BRJ MOD - PLAC 
MVC, Nm 280 ± 51 280 ± 36 217 ± 53 ∂ 212 ± 39 ∂ 208 ± 44 ∂ 202 ± 38 ∂ 275 ± 47 *†‡ 268 ± 47 *†‡ 
MVC % BSL   -21 ± 12 -22 ± 11 -26 ± 10 -27 ± 9 -1 ± 6 *†‡ -2 ± 7 *†‡ 
10 Hz, Nm 61 ± 11 62 ± 10 27 ± 12 ∂ 22 ± 14 ∂ 20 ± 10 ∂ 23 ± 12 ∂ 46 ± 12 *∂†‡ 40 ± 8 *∂†‡ 
10 Hz % BSL   -56 ± 15 -63 ± 17 -67 ± 13 -64 ± 16 -29 ± 15 *†‡ -34 ± 10 *†‡ 
50 Hz, Nm 140 ± 27 142 ± 21 111 ± 32 ¥ 88 ± 21 ∂ 95 ± 26 ∂ 95 ± 27 ∂ 127 ± 18 *‡ 129 ± 27 *†‡ 
50 Hz % BSL   -18 ± 20 ¥ -35 ± 16 -31 ± 15 -30 ± 20 -9 ± 8 *‡ -10 ± 17 *†‡ 
10/50 Hz Ratio 0.44 ± 0.08 0.44 ± 0.05 0.24 ± 0.07 ∂ 0.24 ± 0.1 ∂ 0.21 ± 0.05 ∂ 0.23 ± 0.05 ∂ 0.36 ± 0.07 *∂†‡ 0.32 ± 0.06 *∂†‡ 
10/50 Hz % BSL   -46 ± 14 -46 ± 15 -52 ± 13 -50 ± 8 -22 ± 13 *†‡ -26 ± 11 *†‡ 
1 Hz, Nm 61 ± 13 63 ± 16 37 ± 12 ∂ 36 ± 9 ∂ 34 ± 10 ∂ 36 ± 14 ∂ 52 ± 13 *†‡ 50 ± 14 *∂†‡ 
1 Hz % BSL   -41 ± 16 -49 ± 17 -44 ± 14 -43 ± 20 -18 ± 13 *†‡ -20 ± 5 *†‡ 
PST, Nm 75 ± 14 77 ± 18 55 ± 19 ∂ 51 ± 13 ∂ 50 ± 13 ∂ 52 ± 16 ∂ 79 ± 18 *†‡ 74 ± 14 *†‡ 
PST % BSL   -29 ± 26 -33 ± 20 -34 ± 14 -27 ± 27 2 ± 10 *†‡ 0 ± 10 *†‡ 
VA, % 90 ± 6 90 ± 6 86 ± 5 88 ± 5 86 ± 5 83 ± 9 90 ± 6 84 ± 11 
VA % BSL   1 ± 5 -2 ± 9 -4 ± 8 -6 ± 10 -1 ± 7 -6 ± 11 
WRpeak, W 891 ± 122 898 ± 186 776 ± 164 ∂ 758 ± 239 701 ± 157 ∂ 735 ± 165 ∂ 896 ± 124 *‡ 914 ± 121 *†‡ 






Value are mean ± SD. BRJ, nitrate supplementation; PLAC, placebo supplementation; BSL, baseline exercise; VH3/8/13/18, very 
heavy-intensity exercise at the 3, 8, 13, and 18-minute time points; LoT, limit of tolerance; MOD, moderate-intensity exercise; MVC, 
maximum voluntary contraction; 1, 10, and 50 Hz involuntary stimulation; 10/50 Hz Ratio, ratio of 10 and 50 Hz involuntary 
stimulation torque; PST, potentiated singlet twitch torque; VA, voluntary activation; WRpeak, peak power output; Nm, newton-meters; 
W, watts. Baseline value comparisons are to the pre-exercise value of each respective ride, not to the group mean baseline values 
displayed. (*) difference (P < 0.05) from previous. (∂) difference (P < 0.05) from baseline. (†) difference (P < 0.05) from VH18. (‡) 
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